p450scc 3beta-hsd abundance increase;block;hpte;0;16737795
p450arom mrna abundance increase;block;hpte;0;16737795
ghrelin;mediate;starvation response;0;12464231
hormone antagonist treatment;suppress;lh concentration;2;20797347
acyline treatment;suppress;lh concentration;2;20797347
contrast;inhibit;ll group;0;21592238
clamp glucose metabolic clearance rate;increase;hypo-osmolality;0;14681716
contrast;increase;corticosterone injection level;0;17064351
gonadotrope cell synthesis;regulate;activin tgf ligand endocrine factor;2;24601881
gonadotrope cell synthesis;regulate;inhibin tgf ligand endocrine factor;2;24601881
estrogen;inhibit;food intake;0;21358146
hypothalamus nucleus npy microinjection;increase;quotient;0;10757510
hypothalamus pvn y microinjection;increase;quotient;0;10757510
hypothalamus pvn npy microinjection;increase;quotient;0;10757510
contrast;suppress;feed;0;10757510
pvn avp;regulate;innervation endocrine gland;0;12067600
pvn ot;regulate;innervation endocrine gland;0;12067600
pvn avp;regulate;tissue;0;12067600
pvn ot;regulate;tissue;0;12067600
fst exposure;increase;plasma acth;2;12652345
bu224 administration;increase;acth;2;12652345
vasopressin;secrete;pituitary gland;2;23121213
vasopressin;regulate;urine secretion;0;23121213
vasopressin;regulate;arteriole tonus;0;23121213
vasopressin;increase;blood pressure;0;23121213
vasopressin;decrease;organ donor catecholamine need;0;23121213
datum;mediate;steroid sex hormone effect;0;11672449
gnih;inhibit;system activity;0;21466656
fsh;increase;akt target mouse double-minute 2 phosphorylation;2;188456361258887512606543126064631283229012869586127612171820443912759245129336731295291510935551109529321096505910998351113067061141599211420129115951841149854211818496119603681196069413130303145758641455971814729330150240781476197715095341149829271498838715056665151697781721381717502379178485741785021418268343153583001527202515337760627177661428193034888251022431534788089148753991885244138754745875661692784219415397941539894729449892015103532511035801414907713155277981532816315690031156134821608106516170383165060551673550016880823170819711671512810537120105518171068344010803590119232801219340112172553121869811224228112149254123763451239943012393646124883271258675512493768
fsh;increase;mdm2 phosphorylation;2;188456361258887512606543126064631283229012869586127612171820443912759245129336731295291510935551109529321096505910998351113067061141599211420129115951841149854211818496119603681196069413130303145758641455971814729330150240781476197715095341149829271498838715056665151697781721381717502379178485741785021418268343153583001527202515337760627177661428193034888251022431534788089148753991885244138754745875661692784219415397941539894729449892015103532511035801414907713155277981532816315690031156134821608106516170383165060551673550016880823170819711671512810537120105518171068344010803590119232801219340112172553121869811224228112149254123763451239943012393646124883271258675512493768
melatonin;suppress;rat system vp release;0;20814074
mch-r2;mediate;mch effect;0;17324419
arginine vasopressin;secrete;pituitary gland;2;12524471
avp;secrete;pituitary gland;2;12524471
arginine vasopressin;secrete;pituitary gland;2;12524471
avp;secrete;pituitary gland;2;12524471
light melatonin level acute inhibition;suppress;contraction;0;25015556
interaction;mediate;gfap;2;199365681568093915745952186558801882396119037321182821601057502011012836115497211219522412372001124924271260949912859353128996821455287414617676147242601513521915134863151537534577217123694870397667199961733880763653286462460638494624127002422592158936411578943040847951592262215961240160149241599570116134141162164211650392016322347165545011681614416832906166449071684276317127302170316681731428617241122176631381767895717628000176930271768401417714952173932981807769418082334183675041829340418439402184627961862606518655876188033081921188119267953379509335675803109879281977024438642451734340445930445183044521318019325651532202017161744384693137891864770847477762337615871884710288096728839353895163689773829354336953012897951471535618715610159
interaction;mediate;gfap;2;199365681568093915745952186558801882396119037321182821601057502011012836115497211219522412372001124924271260949912859353128996821455287414617676147242601513521915134863151537534577217123694870397667199961733880763653286462460638494624127002422592158936411578943040847951592262215961240160149241599570116134141162164211650392016322347165545011681614416832906166449071684276317127302170316681731428617241122176631381767895717628000176930271768401417714952173932981807769418082334183675041829340418439402184627961862606518655876188033081921188119267953379509335675803109879281977024438642451734340445930445183044521318019325651532202017161744384693137891864770847477762337615871884710288096728839353895163689773829354336953012897951471535618715610159
sevoflurane period odour misinterpretation;mediate;melatonin decrease level;2;20962652
purpose;increase;igfbp-4 synthesis;2;11357060
cdna expression cell transfection;increase;medium igfbp-4 accumulation;2;11357060
3 mch 10 pituitary cell treatment;decrease;immunoreactivity area;0;19752150
release reduction;block;mch receptor treatment;2;19752150
release reduction;block;mchr treatment;2;19752150
pituitary lhbeta mrna expression;increase;d1;0;19997478
mapk kinase inhibitor administration;decrease;nt mtii-induced erk phosphorylation;2;15961554
erk pathway activation;suppress;food intake;0;15961554
raphe pallidus neuron;mediate;rat tachycardia;0;17927775
raphe pallidus neuron;mediate;rat fever;0;17927775
gnrh pulsatile secretion;regulate;axis activity;0;11893524
gnrh treatment;inhibit;expression;0;19800342
cpee;increase;glucocorticoid glu release;2;17026532
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
type 3a receptor;activate;serotonin;2;16077169
5-ht3ar;activate;serotonin;2;16077169
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
desmopressin therapy;decrease;sodium;0;210747902107420721503733
contrast;increase;subunit gene;0;19458315
contrast;increase;cga;0;19458315
lhb messenger rna;increase;adcyap1 stimulation;0;19458315
follistatin;increase;gnrh pulse;2;19458315
fst;increase;gnrh pulse;2;19458315
gene expression;increase;gnrh pulse;2;19458315
adcyap1 receptor gene;increase;pulse frequency gnrh;2;19458315
adcyap1r;increase;pulse frequency gnrh;2;19458315
expression;increase;pulse frequency gnrh;2;19458315
gnrh adcyap1;regulate;lhb fshb subunit gene;0;19458315
rhesus monkey luteinize hormone regulation;mediate;testosterone action;2;10718912
rhesus monkey lh regulation;mediate;testosterone action;0;10718912
rhesus monkey secretion regulation;mediate;testosterone action;2;10718912
testosterone feedback action;mediate;cell;0;10718912
lpxrfamide peptide expression;regulate;melatonin;2;21325452
aromatase steroidigenesis enzyme;suppress;peptide;0;20515793
p450 cleavage steroidigenesis enzyme;suppress;peptide;0;20515793
steroidogenenisis gnrh-iii action;suppress;receptor expression;0;20515793
induction;suppress;gnrh-iii;2;20515793
mouse;decrease;fast blood glucose level increase insulin sensitivity;2;23665701
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
hormone-releasing hormone;inhibit;lhrh;2;11502441
lhrh;inhibit;lhrh;0;11502441
luteinize hormone;secrete;pituitary gland;2;117167819459445946250695289629748280985698999209011034284310966476109999411139542176512210088338530170070263909829301225228199942819996312972425373672178999211603621659472123549133284513330527988482782386176219818524874854881586035748602223863569186748378701085875672690030259012799911612590692529099910911525491825819405622
progesterone lh fsh;increase;5 min;0;16698221
cortisol;increase;5 min;0;16698221
pgf group progesterone;decrease;40 min;0;16698221
pgf group;decrease;45 min;0;16698221
ghrelin;activate;dog axis;0;12431802
sga hypothalamic h1 receptor;activate;ampk;2;23640535
treatment;activate;palmitoyltransferase 1;2;23640535
sga h1 receptor antagonism;activate;palmitoyltransferase 1;2;23640535
pgfm concentration;increase;be;0;20626675
cortisol concentration;increase;be;0;20626675
lh;decrease;be;0;20626675
nmda increase dose incubation;decrease;vasopressin release;2;11012837
kainate increase dose incubation;decrease;vasopressin release;2;11012837
ampa increase dose incubation;decrease;vasopressin release;2;11012837
cortisol;increase;bp;0;17386356
datum;increase;hb size;0;1589457627641358968267753792674855718612404863949190406969362271957515896612039746481984147998146169926800102297331047144815709954109937491064468412003834120427761200656712235032122350501280502412826074127944261281674614595407147454611459293814990349115446734786948765210877982088979928156623
datum;increase;hb size;0;1589457627641358968267753792674855718612404863949190406969362271957515896612039746481984147998146169926800102297331047144815709954109937491064468412003834120427761200656712235032122350501280502412826074127944261281674614595407147454611459293814990349115446734786948765210877982088979928156623
study;mediate;norepinephrine release effect;2;12654704
arousal;inhibit;serotonin opioid;2;19686432
pvn;decrease;period;0;15193530
pvn;increase;period;0;15193530
treatment;inhibit;testosterone level;2;19826459
leukocytic ldh activity;increase;animal blood glucose increase;2;24258289
study;inhibit;lh surge;2;12698976
igf-i plasma level;increase;activity elevation;0;19456398
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
glucocorticoid action;increase;food salience;0;15240363
glucocorticoid action;increase;food ingestion;0;15240363
gnrh neuron function;regulate;gnrh gene transcription;0;23531789
gnih synthesis;regulate;secretion rhythm;0;23531789
gnih release;regulate;secretion rhythm;0;23531789
gnih synthesis;regulate;secretion rhythm;0;23531789
gnih release;regulate;secretion rhythm;0;23531789
contrast;increase;stimulation site distance;0;14672999
ghrelin;increase;food intake;0;22074955
ghrelin;decrease;energy output;0;22074955
protein kinase inhibitor cell incubation;suppress;lh effect;2;17068133
protein kinase inhibitor cell incubation;suppress;lh effect;2;17068133
tgf-alpha cell incubation;increase;cox2 protein level;0;17068133
melatonin;inhibit;dehydrogenase mrna expression;0;146731861058083575680071122979811231993113061771160054211691640119331581193710712062316123905041251988942215504223909864118687001099183569951887197099699737724991881810203008105098026745194623853160989763020078282800232193822926312272146027371542301642215842723385331848566164984119578861750475163993783817968319592839657883707078262008827443080773117964299776208376062534310502435263243638471748941870572215274956806258436701117862639396275916695225126331310601975
comparison;increase;acth corticosterone level;2;14654444
75 body weight flavonoid quercetin combine administration;suppress;tissue hydrogen peroxide production lipid peroxidation;2;21337715
pco therapy;decrease;fin leptin level;0;14680609
pituitary gland;inhibit;gaba release;0;12488823
tgfbeta;secrete;neurohypophysis;0;15214860
tgfbeta;regulate;pituitary cell proliferation;0;15214860
tgfbeta;regulate;pituitary cell secretion;0;15214860
testosterone level;increase;group;0;17179656
body weight;decrease;incb13739 therapy placebo;2;20413513102320521727240015793240158119281610340916135025112385411125091411418628115467661173995712840062146788651504760715356040268127315387169405715167055501724477910480450
urine cortisol;suppress;dose suppression test 95 %;0;2316643210720040181742871291567912930931145023621467118718322123034617955456786218487840669005978906150897687009793762103576961571765910857554
pvn avp neuron;activate;depression;0;17524488
progesterone receptor;mediate;sex;0;23899762
progesterone receptor;mediate;sex;0;23899762
progesterone receptor;mediate;status behavior;0;23899762
progesterone receptor;mediate;status behavior;0;23899762
gh acth concentration;decrease;cat somatostatin analog octreotide administration;0;18801640
cortisol concentration;decrease;cat somatostatin analog octreotide administration;0;18801640
receptor;regulate;estrogen;2;11963827
rhesus monkey luteinize hormone regulation;mediate;testosterone action;2;10718912
rhesus monkey lh regulation;mediate;testosterone action;0;10718912
rhesus monkey secretion regulation;mediate;testosterone action;2;10718912
testosterone feedback action;mediate;cell;0;10718912
plasma estrogen elevation;inhibit;estrus;0;23171609723013862865866757234668372965408073710923332057328374482852091204687120702611908711193742419407131099383711417685126064051283692253883585062726434577112550949083593365956409865284177001009720253271941231500551904858491095989353176104619841354809717027203196788682085224820875680
hypothalamic tuberoinfundibular dopaminergic;inhibit;prolactin;0;2046305410940733286942511739329352050935532202887254246249519770852088869850477181047787909141791040979141338934515900920092022279247269930624693845729724019102018191022198910510245153456801556432411826263118976834706010894170102616678059073081421575554316254185164326281785344018096658191715661950022619299456731779861193216141934399553911517260
hypothalamic tuberoinfundibular dopaminergic;inhibit;prl;0;2046305410940733286942511739329352050935532202887254246249519770852088869850477181047787909141791040979141338934515900920092022279247269930624693845729724019102018191022198910510245153456801556432411826263118976834706010894170102616678059073081421575554316254185164326281785344018096658191715661950022619299456731779861193216141934399553911517260
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
vasopressin;increase;left ventricular;0;18541142
vasopressin;increase;lv;0;18541142
circuitry part pvn;mediate;ghrelin property;2;12948845
treatment;increase;acth;2;21687973
treatment;increase;lh;2;21687973
somatostatin;increase;pip (2)- level;0;15784846
somatostatin;decrease;level;0;15784846
d-npy27-36;decrease;78 %;0;15572203
sertolus cell product dhh;secrete;testosterone;2;22568218
four rat;suppress;testicular testosterone;2;12606480
estrogen;suppress;release pulse amplitude pulse frequency;0;15842235
insulin;increase;secretion;0;16236542
glucose;increase;secretion;0;16236542
leptin;increase;muscle glucose uptake;2;16236542
leptin;increase;oxidation;2;16236542
leptin;suppress;glucose output;2;16236542
per1 expression;mediate;response element;0;17483911
lh;regulate;clock;0;17483911
sf-1;regulate;acth;2;15261303
igf;regulate;follicular development;0;20130263115222929811848122415451195616611985604121281041037990010491647158369551581490116306079164390931695984316943367169317671733252017218136175074771919780419443782105997451072100310803590109131211113416311223367112455771131678511513734124936981258677812714278127954261472659614973274150874301529743913723227758431754569987726038813730972216311713222
igf;regulate;steroidogenesis;0;20130263115222929811848122415451195616611985604121281041037990010491647158369551581490116306079164390931695984316943367169317671733252017218136175074771919780419443782105997451072100310803590109131211113416311223367112455771131678511513734124936981258677812714278127954261472659614973274150874301529743913723227758431754569987726038813730972216311713222
igf protein;inhibit;action;0;20130263115222929811848122415451195616611985604121281041037990010491647158369551581490116306079164390931695984316943367169317671733252017218136175074771919780419443782105997451072100310803590109131211113416311223367112455771131678511513734124936981258677812714278127954261472659614973274150874301529743913723227758431754569987726038813730972216311713222
igfbp;inhibit;action;0;20130263115222929811848122415451195616611985604121281041037990010491647158369551581490116306079164390931695984316943367169317671733252017218136175074771919780419443782105997451072100310803590109131211113416311223367112455771131678511513734124936981258677812714278127954261472659614973274150874301529743913723227758431754569987726038813730972216311713222
igfbp proteolysis;regulate;igf bioavailability;0;20130263115222929811848122415451195616611985604121281041037990010491647158369551581490116306079164390931695984316943367169317671733252017218136175074771919780419443782105997451072100310803590109131211113416311223367112455771131678511513734124936981258677812714278127954261472659614973274150874301529743913723227758431754569987726038813730972216311713222
rottlerin;inhibit;erk;2;15048868
pkcdelta inhibitor;inhibit;erk;2;15048868
pkcdelta inhibitor;inhibit;kinase phosphorylation;0;15048868
pkcdelta inhibitor;inhibit;cell proliferation;0;15048868
interaction;mediate;gfap;2;199365681568093915745952186558801882396119037321182821601057502011012836115497211219522412372001124924271260949912859353128996821455287414617676147242601513521915134863151537534577217123694870397667199961733880763653286462460638494624127002422592158936411578943040847951592262215961240160149241599570116134141162164211650392016322347165545011681614416832906166449071684276317127302170316681731428617241122176631381767895717628000176930271768401417714952173932981807769418082334183675041829340418439402184627961862606518655876188033081921188119267953379509335675803109879281977024438642451734340445930445183044521318019325651532202017161744384693137891864770847477762337615871884710288096728839353895163689773829354336953012897951471535618715610159
interaction;mediate;gfap;2;199365681568093915745952186558801882396119037321182821601057502011012836115497211219522412372001124924271260949912859353128996821455287414617676147242601513521915134863151537534577217123694870397667199961733880763653286462460638494624127002422592158936411578943040847951592262215961240160149241599570116134141162164211650392016322347165545011681614416832906166449071684276317127302170316681731428617241122176631381767895717628000176930271768401417714952173932981807769418082334183675041829340418439402184627961862606518655876188033081921188119267953379509335675803109879281977024438642451734340445930445183044521318019325651532202017161744384693137891864770847477762337615871884710288096728839353895163689773829354336953012897951471535618715610159
aii;mediate;pvn excitability;2;10795918
melatonin;inhibit;substance ot secretion;0;15613740
tgfalpha;increase;incorporation;0;11700850
pd0 testis culture growth factor stimulation;suppress;tgfalpha mrna expression;2;11700850
tgfalpha egfr expression;regulate;fsh growth stimulatory hormone;0;11700850
tgfalpha egfr expression;regulate;testosterone growth stimulatory hormone;0;11700850
lh luteinize dose;increase;progesterone secretion;0;12972376
lh 128 ng\ per ml;increase;progesterone secretion;0;12972376
fsh luteinize dose;increase;progesterone secretion;2;12972376
fsh 128 ng\ per ml;increase;progesterone secretion;2;12972376
glucocorticoid;suppress;hormone;0;1928228610551782178959071071989110811881108442391156471012022233124038321257852912639969128081071461554014576178145819332996774242897830725351968447840805581191887802409772981513695938558240870277891369309139717923472395452249858532103726621604137216208279162491781664185516675526168396611706598210692139
glucocorticoid;suppress;gnrh;0;1928228610551782178959071071989110811881108442391156471012022233124038321257852912639969128081071461554014576178145819332996774242897830725351968447840805581191887802409772981513695938558240870277891369309139717923472395452249858532103726621604137216208279162491781664185516675526168396611706598210692139
gc;suppress;gnrh;2;1928228610551782178959071071989110811881108442391156471012022233124038321257852912639969128081071461554014576178145819332996774242897830725351968447840805581191887802409772981513695938558240870277891369309139717923472395452249858532103726621604137216208279162491781664185516675526168396611706598210692139
glucocorticoid;suppress;gene;0;1928228610551782178959071071989110811881108442391156471012022233124038321257852912639969128081071461554014576178145819332996774242897830725351968447840805581191887802409772981513695938558240870277891369309139717923472395452249858532103726621604137216208279162491781664185516675526168396611706598210692139
glucocorticoid;suppress;expression;0;1928228610551782178959071071989110811881108442391156471012022233124038321257852912639969128081071461554014576178145819332996774242897830725351968447840805581191887802409772981513695938558240870277891369309139717923472395452249858532103726621604137216208279162491781664185516675526168396611706598210692139
recombination;mediate;posterior pituitary gland;2;23209739106866071106533811069887110878301110505511105057113010011198085015223342631940014959759177348168504731806467620147377202372812038673220890044
transport;increase;plasma cortisol;2;16632387
npy;inhibit;release;0;11287104
hand;block;lh release stimulation;2;11287104
mu administration;block;lh release stimulation;2;11287104
research;mediate;differ response;0;12743542
sodium reabsorptive mechanism;upregulate;vasopressin escape;2;11158210
hsd;increase;gamma-msh plasma concentration;2;12501973
crh;regulate;acth receptor expression;2;17959886
crh;regulate;acth receptor expression;2;17959886
crh;regulate;acth receptor expression;2;17959886
crh;regulate;acthr expression;2;17959886
crh;regulate;acthr expression;2;17959886
crh;regulate;acthr expression;2;17959886
raus therapy preparation;increase;retention;0;23843834
heme oxygenase;regulate;arginin-vasopressin neuropeptide release;2;20097264
contrast;decrease;pachytene spermatocyte;0;10906069
contrast;decrease;spermatid;0;10906069
gfap;decrease;diabetes onset;0;16873533
exposure;increase;adipose tissue;2;18285526
t (3)- dose;increase;adipose tissue;2;18285526
activate;regulate;adrenaline;2;24100548
hypothalamus action;suppress;glucose production;2;24937445
arginine vasopressin;mediate;behavior hormone effect;0;10838478
drug;increase;lh fsh;2;20843951
datum;regulate;body temperature;0;23538704
datum;regulate;energy homeostasis;0;23538704
apparatus;inhibit;gnrh pulse generator;2;12051595
dnmt3b2;increase;spermatogonium;0;15567719
dnmt3b isoform;increase;spermatogonium;0;15567719
75 body weight flavonoid quercetin combine administration;suppress;tissue hydrogen peroxide production lipid peroxidation;2;21337715
oxytocin receptor;suppress;progesterone;2;17765941
otr;suppress;progesterone;2;17765941
expression;suppress;progesterone;2;17765941
insulin concentration;increase;september;0;18401941
growth hormone;increase;ghrelin i.c.v. administration;2;11089570
gh;increase;ghrelin i.c.v. administration;2;11089570
hormone;inhibit;ghrelin administration;2;11089570
tsh;inhibit;ghrelin administration;2;11089570
increase il-1;regulate;norepinephrine;2;23671261
sirt1;activate;restriction response;0;23950036
exogenous glucocorticoid administration;downregulate;vasopressin;0;10795903
exogenous glucocorticoid administration;increase;receptor v1b receptor mrna facilitate coupling;0;10795903
glucocorticoid interaction;regulate;v1b receptor mrna expression;0;10795903
vasopressin interaction;regulate;v1b receptor mrna expression;0;10795903
maturation;block;pkaus activator 8-aha-camp;2;23028418
pkaus subunit level;decrease;fsh stimulation;0;23028418
pkaus subunit level;increase;fsh stimulation;0;23028418
pkaus activation;inhibit;protein kinase;0;23028418
pkaus activation;inhibit;mapk;0;23028418
cortisol;increase;bp;0;17386356
halothane administration;increase;serum glucose;2;17988436
avp;mediate;acth response;2;11488255
ot;mediate;acth response;2;11488255
vitro;inhibit;acth secretion;2;11488255
tgfbeta;secrete;neurohypophysis;0;15214860
tgfbeta;regulate;pituitary cell proliferation;0;15214860
tgfbeta;regulate;pituitary cell secretion;0;15214860
vasopressin concentration;increase;one;0;11990905
insulin curve area;decrease;group;0;16483179
fast insulin curve area;decrease;group;0;16483179
testosterone level;decrease;group;0;16483179
melatonin;suppress;rat system vp release;0;20814074
hormone vasopressin;regulate;water clearance;0;21691126
testosterone;increase;altitude group;0;16380390
lh;regulate;secretion;0;17991618
lh;regulate;secretion;0;17991618
e (2)-;decrease;nidopallium perk;2;22294743
e (2)-;decrease;hp perk;2;22294743
tumor cell tr4 force overexpression;increase;proopiomelanocortin transcription acth secretion proliferation;2;23653479
dopamine;activate;production;0;15909246
next gnrh antagonist-treated rat;block;action;0;19136390
next gnrh antagonist-treated rat;block;action;0;19136390
glucocorticoid;suppress;glutamate release;0;19144839
ghrelin;activate;dog axis;0;12431802
d-ghrelin;increase;mouse 2 food consumption;0;19445969
contrast;increase;hypothalamus release;0;15473128
dopamine;suppress;release elevation;0;20553721
result;decrease;acid reactive substance radical-trapping antioxidant;2;22012612
vegf secretion;inhibit;ang iii ang iv;0;22442002
hormone network;secrete;adipose tissue;2;17485320
bupropion;inhibit;norepinephrine;2;19039677
antidepressant bupropion;inhibit;dopamine;2;22512539
contrast;increase;gland secretion;0;12723886
hand;decrease;pkc activity;2;10944431
carbachol bst treatment;increase;plasma vasopressin level;2;21466795
buspirone;increase;insulin level;2;15802819
quit rate;increase;pharmacotherapy use;2;16517193
contrast;increase;percentage nkt cell number;0;19996489
contrast;increase;cell percentage number;0;19996489
m;increase;serotonin level;2;23669068
vasopressin;regulate;aqp2 mrna expression;0;12151754
vasopressin;secrete;neurohypophysis;0;12418301
disulfiram;inhibit;acetaldehyde oxidation;2;12107032
ad microglium;increase;research effort;2;23930978
somatostatin;decrease;rat activity;0;19414189
igfbp6 downregulation;activate;pi3 pathway;0;24379119
pituitary growth hormone;increase;e16;0;21168412
pituitary growth hormone;increase;growth;0;21168412
pituitary growth hormone;increase;e20;0;21168412
vip;increase;erk1;2;10940738
pacap38;increase;erk1;2;10940738
vip;increase;erk2 phosphorylation;2;10940738
pacap38;increase;erk2 phosphorylation;2;10940738
erk2 vip pacap38 activation;block;protein kinase;0;10940738
erk2 vip pacap38 activation;inhibit;erk2 vip pacap38 activation;0;10940738
erk2 vip pacap38 activation;inhibit;erk2 vip pacap38 activation;0;10940738
vip;activate;erk;2;10940738
pacap38;activate;erk;2;10940738
drinking;increase;blood glucose level;2;19485973
crf-r1 mrna expression reduction;inhibit;pka pretreatment;2;12121497
amygdala\ per hippocampus drd5 sstr3 htr3a decrease mrna level;regulate;ngf;0;21820738
amygdala\ per hippocampus gene decrease mrna level;regulate;ngf;0;21820738
compartment 1 glucose distribution space glucose mass;increase;cow;0;11814033
compartment 1 glucose residence time;increase;cow;0;11814033
compartment 1 glucose distribution space glucose mass;decrease;cow;0;11814033
compartment 1 glucose residence time;decrease;cow;0;11814033
cumulus cell progesterone synthesis;block;smad2\ per 3 activation;0;21520325
vasopressin infusion;decrease;norepinephrine requirement;2;21892977
research;regulate;pathway;0;19637976
research;regulate;pathway;0;19637976
pka activation;activate;activity;0;21924340
pregnancy uterus myometrium receptor mrna protein concentration increase contrast;increase;animal;0;11967183
noradrenaline response;mediate;response;0;21146475
noradrenaline response;mediate;response;0;21146475
cell exposure;inhibit;transcription level vegf secretion;2;24176035
gnrh analog administration;suppress;function;0;11787159
rt oscillation;suppress;methylphenidate;2;15950016
rat testis nse effect;inhibit;lipid peroxidation process;2;21328874
growth factor;increase;dopamine 2 receptor expression;2;22684586
ngf;increase;dopamine 2 receptor expression;2;22684586
ngf;increase;d2r expression;0;22684586
djdat hyperactivity;suppress;sch23390 sulpiride pretreatment;0;24858686
hypothalamus somatostatin ghrh release regulation;regulate;neuropeptide range;0;16586030
hypothalamus somatostatin ghrh release regulation;regulate;neurotransmitter range;0;16586030
hypothalamus somatostatin ghrh release regulation;regulate;neurohormone range;0;16586030
rat testis change;decrease;rat testosterone level;2;18395915
rat behavior change;decrease;rat testosterone level;2;18395915
ac\ per camp\ per pka signaling pathway;regulate;secretion function;0;21388404
pi3k\ per akt pathway signaling pathway;regulate;secretion function;0;21388404
ac\ per camp\ per pka signaling pathway;regulate;cell proliferation function;0;21388404
pi3k\ per akt pathway signaling pathway;regulate;cell proliferation function;0;21388404
insulin administration;decrease;activity;0;24582678
hspc migration;decrease;cd44 expression;2;15813854
net inhibitor reboxetine administration;increase;dopamine efflux;2;21669025
3 administration;increase;dopamine efflux;2;21669025
psychostimulant amphetamine administration;increase;dopamine efflux;2;21669025
0.5 mg\ per kg administration;increase;dopamine efflux;2;21669025
cocaine administration;increase;dopamine efflux;2;21669025
10 mg\ per kg administration;increase;dopamine efflux;2;21669025
verapamil;inhibit;la3 + secretion;0;16515555
chloralhydrate;inhibit;function;0;12548383
somatostatin;activate;current;0;10805669
reuptake inhibitor;increase;serotonin concentration;2;12690637
ect;increase;serotonin concentration;2;12690637
mao;increase;serotonin concentration;2;12690637
ect bupropion mao inhibitor;increase;noradrenaline concentration;2;12690637
lithium;increase;serotonin concentration increase;2;12690637
fmrp;regulate;insulin signaling pathway;2;22513101
interaction;mediate;gfap;2;19936568
interaction;mediate;gfap;2;19936568
acth;suppress;childhood seizure type;0;17368435
mch;inhibit;glutamatergic gabaergic lh neuron activity;2;11351031
disulfiram;increase;drug therapy efficacy;2;10841824
bupropion;inhibit;dopamine reuptake;2;20140131
mch;regulate;erk activity;2;23449013
receptor;regulate;erk activity;2;23449013
progesterone;inhibit;gnrh pulse frequency;2;12698972
oestradiol;increase;gnrh pulse frequency;2;12698972
cell alpha-msh release regulation;regulate;ca2 + channel activity;0;14511978
replacement therapy;increase;birth defect risk;0;22534270
v2 vasopressin receptor;activate;g;0;16115624
research;mediate;da release;0;24484986
n-methyltransferase inhibitor;inhibit;ic50 1.9 microm;0;11900856
n-methyltransferase substrate;inhibit;2n-methyltransferase activity;0;11900856
varenicline therapy mh encounter;increase;29 %;0;20966147
rodent;mediate;mchr1 receptor;2;17237257
mch action;mediate;mchr1 receptor;0;17237257
microm thp;decrease;dopamine content;2;16026929
atomoxetine reuptake inhibitor;increase;dopamine concentration;2;15115947
melatonin administration;increase;animal survival time;0;16180084
tumor rat;increase;melatonin administration;2;16180084
prolactin;inhibit;dopamine;2;25453900
prl;inhibit;dopamine;2;25453900
evidence;regulate;fuel supply i.e. glucose;2;16236383
inability;regulate;glucose;2;16236383
at-t20 cell;decrease;pomc gene promoter activity;2;21356276
lxr overexpression;decrease;pomc gene promoter activity;2;21356276
gnrh antagonist;inhibit;gnrh receptor blockage pituitary gland;0;15018588
contrast;decrease;l-time;0;17331587
contrast;decrease;l;0;17331587
contrast;decrease;t-td;0;17331587
stat3 hct116 transfectant sirna attenuate pttg expression;suppress;cell growth;0;23416975
stat3 hct116 transfectant sirna attenuate pttg expression;suppress;colony formation;0;23416975
result;regulate;rat plasma epinephrine;2;16026475
result;regulate;differential sensitivity plasma epinephrine;2;16026475
observation;mediate;il-1beta glucocorticoid effect;2;12538636
oxidative stress;increase;stress repetition;0;22787054
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
npy;increase;redox potential;0;23211512
treatment;decrease;insulin release;2;23211512
shp2 inhibitor mouse injection;block;ssc cell production;0;24123360
administration;decrease;growth hormone;2;15930173
igf-i concentration;decrease;lp;0;15930173
liver igfbp-3 gene expression;decrease;lp;0;15930173
kidney igfbp-3 gene expression;decrease;lp;0;15930173
circulate level igfbp-3 gene expression;decrease;lp;0;15930173
dexamethasone pretreatment;decrease;igfbp-3 proteolysis;2;15930173
inhibition;inhibit;gnrh secretion;2;12186689
brain region constitutive tnf-alpha;decrease;clonidine administration;0;11473862
lh excretion;increase;69.5 %;0;12676335
glucocorticoid;regulate;process;0;18600567
compound;inhibit;rat pituitary corticotrope crf-stimulated acth release;2;15867951
protein;upregulate;l beta t2 cell gnrh treatment;2;15128600
contrast;decrease;gaba;0;11430864
contrast;decrease;b;0;11430864
contrast;decrease;saclofen;0;11430864
cpee;increase;glucocorticoid glu release;2;17026532
cholineacetyltransferase;decrease;hypothalamic;0;11354244
cholineacetyltransferase;decrease;brain region;0;11354244
leptin;secrete;adipose tissue;2;11327106
aii;mediate;pvn excitability;2;10795918
methylphenidate;increase;level;0;18978488
effect;mediate;d1 degradation;2;20237271
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
glucocorticoid action;increase;food salience;0;15240363
glucocorticoid action;increase;food ingestion;0;15240363
effect;block;lhr activation;2;23603402
contrast;increase;lh;2;16891115
cetrorelix concentration;increase;lh;2;16891115
emission compute tomography study;decrease;area blood flow;0;11588994
plasma vasopressin level;increase;period;0;17258819
result;increase;vasopressin half-life;2;17258819
contrast;increase;activity;0;24955880
release;increase;chicken pituitary gland;2;24955880
study;increase;serotonin level;2;20816814
study;increase;dopamine level;2;20816814
ssrus administration;increase;serotonin level;2;20816814
sertraline administration;increase;dopamine concentration;2;20816814
sertraline administration;increase;dopamine concentration;2;20816814
vasopressin type 2 receptor antagonist;increase;heart failure case water clearance;0;15675332
ltp;block;pka;2;19776361
dopamine transporter blockade;increase;dopamine concentration;0;18480679
amphetamine;increase;dopamine release;2;24191257
methylphenidate;inhibit;dopamine reuptake;0;24191257
methylphenidate;inhibit;norepinephrine reuptake;0;24191257
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
cytotoxic bombesin analog an-215;inhibit;ag carcinoma growth;2;14508826
gastric carcinoma;inhibit;bombesin an-215;0;14508826
somatostatin receptor concentration tumor;suppress;cytotoxic somatostatin an-238;0;14508826
therapy;secrete;hormone;0;19523354
child;block;dat;2;12898575
research;mediate;differ response;0;12743542
adrenaline noradrenaline treatment;increase;level;0;20146024
crystalloid fluid;increase;volume;0;18788373
hypothalamus protein kinase phosphorylation;decrease;cck coinjection;2;24735891
hypothalamus ampk phosphorylation;decrease;cck coinjection;0;24735891
hypothalamus ampk phosphorylation;decrease;leptin coinjection;0;24735891
cck coinjection;increase;cart\ per trh;0;24735891
alcohol treatment;increase;plasma acth cort level;2;22384198
ne transporter 2 action;mediate;brain norepinephrine part;2;11131159
baclofen;increase;sedation;2;18840257
vasopressin;increase;crh1 receptor mrna level;0;11337090
therapy;increase;abstinence rate;0;12215235
therapy;increase;abstinence rate;0;12215235
therapy;increase;abstinence rate;0;12215235
dsf breast cancer treatment;activate;akt signaling;2;20424113
gnrh treatment;increase;1.60;0;23451171
cart expression;regulate;glucocorticoid environment;2;15138156
release;regulate;glucocorticoid environment;2;15138156
gh signaling down-regulation;block;carcinogenesis;2;18079205
gh signaling down-regulation;block;carcinogenesis;2;18079205
tyramine;activate;net norepinephrine transport;2;23450822
dopamine;regulate;behavior;0;25257296
goldfish prp;inhibit;lh expression;2;21703272
hypothalamus pvn;mediate;no action;0;12492777
melatonin;inhibit;substance ot secretion;0;15613740
growth hormone;regulate;fuel homeostasis;0;15268648
growth hormone;regulate;fuel homeostasis;0;15268648
somatostatin;inhibit;stimulate secretion;0;11290377
body plethysmography;increase;rr;0;22019985
gnrh agonist treatment;suppress;mrna expression;0;12921701
methylphenidate;increase;activity;0;22426162
venlafaxine;inhibit;serotonin reuptake;2;12892015
antidepressant;inhibit;serotonin reuptake;2;12892015
search;inhibit;substance;0;12015296
datum;mediate;caffeine effect;0;17055161
adrenaline;inhibit;insulin release;0;12172702
agonist;inhibit;insulin release;2;12172702
metastin\ per kisspeptin-gpr 54 signaling;regulate;gnrh release two mode;2;17377846
neuron population;mediate;estrogen feedback action;2;17377846
ghrelin;increase;feed;0;17454854
atropine l-arginine ondansetron pretreatment;inhibit;ghrelin effect;2;17454854
d-lys3 pretreatment;inhibit;ghrelin effect;2;17454854
ghrp-6 pretreatment;inhibit;ghrelin effect;2;17454854
igf-1 co-incubation;decrease;brdu-labelling;0;16133120
1 oestradiol igf-1 co-incubation;decrease;pkc isoform;0;16133120
1 oestradiol igf-1 co-incubation;decrease;activate erk1\ per 2 level;2;16133120
cocaine mu opioid agonist;increase;dopamine concentration;2;12669175
gnrh antagonist;block;lh increase;0;10855688
tgfbeta;secrete;neurohypophysis;0;15214860
tgfbeta;regulate;pituitary cell proliferation;0;15214860
tgfbeta;regulate;pituitary cell secretion;0;15214860
summary;decrease;increase plasma igf-i concentration st response;2;11881928
est grow horse treatment;decrease;increase plasma igf-i concentration st response;2;11881928
accordance;increase;chemotherapeutic agent effect;2;19706685
flux obstruction;increase;chemotherapeutic agent effect;2;19706685
in2-ghrelin variant mrna level;increase;pit;0;17496153
in2-ghrelin variant mrna level;decrease;obese mouse hpt;0;17496153
in2-ghrelin variant mrna level;decrease;obese mouse pit;0;17496153
disulfiram;inhibit;dopamine beta-hydroxylase;2;10723850
disulfiram;decrease;norepinephrine synthesis;2;10723850
ngf treatment;increase;subtype characteristic receptor;0;14500754
treatment withdrawal;increase;ngf;2;14500754
receptor;increase;ngf;2;14500754
hormone synthesis proliferation pituitary estrogen effect;mediate;estrogen receptor;0;10650942
hormone synthesis regulation pituitary estrogen effect;mediate;estrogen receptor;0;10650942
hormone synthesis proliferation pituitary estrogen effect;mediate;er;0;10650942
hormone synthesis regulation pituitary estrogen effect;mediate;er;0;10650942
lh neurone;activate;fast hypoglycemia;0;12679367
contrast;decrease;complication;0;16669974
glucocorticoid;mediate;receptor;0;18399546
glucocorticoid;mediate;receptor;0;18399546
glucocorticoid;mediate;gr;0;18399546
glucocorticoid;mediate;gr;0;18399546
melatonin;secrete;bloodstream;0;24846082
melatonin;inhibit;ser307 phosphorylation;0;24846082
melatonin;increase;glut-4 expression;0;24846082
somatostatin;regulate;cell proliferation;0;24163059
somatostatin;inhibit;growth factor secretion;0;24163059
hepatocarcinoma;mediate;stress;0;24163059
pituitary corticotrope adrenocorticotropic hormone;increase;inflammation;0;12624539
pituitary corticotrope acth;increase;inflammation;0;12624539
aii;mediate;pvn excitability;2;10795918
akt phosphorylation level;regulate;liver;0;24173540
erk phosphorylation level;regulate;liver;0;24173540
akt phosphorylation level;regulate;muscle;0;24173540
erk phosphorylation level;regulate;muscle;0;24173540
dexamethasone;suppress;lh release;2;12969239
antidepressant;block;noradrenaline;2;22419332
tca;block;noradrenaline;2;22419332
contrast;increase;adenosine effect;0;10691246
contrast;increase;30 nm effect;0;10691246
contrast;mediate;affective state;0;16545872
u-69593;decrease;dat protein;2;11125013
pvn activation;increase;ventilation;0;20708107
pvn activation;increase;volume;0;20708107
pvn activation;increase;frequency;0;20708107
pvn activation;increase;blood pressure;0;20708107
pvn activation;increase;heart rate;0;20708107
da uptake dat binding kappa-agonist action;mediate;mechanism;0;11125013
pvn activation;increase;nerve activity;0;20708107
datum;suppress;tumor gh prl secretion;0;12466351
vitro progesterone;increase;e (2)- secretion;0;17977590
il-6;increase;mek activation;2;16899572
adrenaline noradrenaline treatment;increase;level;0;20146024
crf-r1 mrna expression reduction;inhibit;pka pretreatment;2;12121497
leptin;increase;lh secretion;2;11264725
ischemia gh 1 2 mg\ per kg dose;decrease;lipid peroxidation level;2;21439711
ischemia\ per reperfusion gh 1 2 mg\ per kg dose;decrease;lipid peroxidation level;2;21439711
haloperidol;increase;npy-li;2;10931533
haloperidol;increase;npy-li;2;10931533
contrast;decrease;npy-li tissue level;2;10931533
change;mediate;plasma cortisol surge;2;17138651
neuron datum;increase;prime vesicle amount;0;22905234
datum;increase;prime vesicle amount;0;22905234
neuron datum;increase;exocytosis amount;0;22905234
datum;increase;exocytosis amount;0;22905234
epileptic discharge;increase;electroencephalography;2;19735986
research;mediate;change;0;18977208
body plethysmography;increase;rr;0;22019985
estrogen;decrease;female caffeine substance efficacy;0;24681088
breath co (2)-;increase;plasma cortisol level;2;16962720
clonidine;increase;dopamine output;2;18977208
0.003 mg\ per kg;increase;dopamine output;2;18977208
i.p.;increase;dopamine output;2;18977208
sgaanat1;regulate;signal;0;24039227
sgaanat1;regulate;clock system;0;24039227
fluoxetine activity;mediate;serotoninergic receptor pathway effect;2;21098897
prolactin;inhibit;dopamine;2;25453900
prl;inhibit;dopamine;2;25453900
adipogenesis;mediate;glucocorticoid;2;24297897
adipocyte precursor cell conversion;mediate;glucocorticoid;2;24297897
dexras1;mediate;obesity;0;24297897
gnrh3;upregulate;female brain;0;23174456
gnrhr1a;upregulate;female brain;0;23174456
contrast;mediate;affective state;0;16545872
pituitary gland;inhibit;gaba release;0;12488823
rfrp-3;suppress;rat gnrh-stimulated lh secretion;2;18653621
gh;suppress;glucose tolerance test;2;17033266
lh;suppress;injection;0;11109973
agrp mrna pomc ratio;decrease;rat;0;10875247
npy concentration;increase;14 patient 12;0;11181849
summary;decrease;increase plasma igf-i concentration st response;2;11881928
est grow horse treatment;decrease;increase plasma igf-i concentration st response;2;11881928
buspirone;block;d2 dopamine presynaptic;2;19024168
5-hydroxytryptaminelum autoreceptor agonist;block;d2 dopamine presynaptic;2;19024168
result;mediate;insulin hormone effect;2;18479830
hormone;secrete;gnrh neuron;2;17706588
gnrh;secrete;gnrh neuron;0;17706588
study;increase;poly-therapy trend;2;23349595
gnih;inhibit;release;0;16902951
gnih;inhibit;gnrh release;0;16902951
cart;inhibit;glucose stimulate insulin secretion;2;16842887
fluoxetine;inhibit;testosterone level;2;20864192
54 g\ per l;inhibit;testosterone level;2;20864192
tumor cell tr4 force overexpression;increase;proopiomelanocortin transcription acth secretion proliferation;2;23653479
saccharomyce;activate;protein kinase;0;11121776
saccharomyce;activate;mapk;0;11121776
saccharomyce;activate;cascade;0;11121776
hes1 hey1;activate;p53;2;14990790
tfap4;activate;p53;2;14990790
stat3 mutant;inhibit;growth;0;12646574
aggrecan type ii collagen amount;decrease;degenerative group;0;25433723
far1 pool;regulate;cdc24 access;2;11121776
rptp number;regulate;rptk protein activity;2;23814054
1 bfa pretreatment;increase;pip2 signal;2;16741017
ghrelin;suppress;nerve activity;0;25505608
ghrelin;suppress;csna;0;25505608
pdgf-bb response pdgfbeta receptor phosphorylation;inhibit;syk inhibitor;0;19038866
p21 interfere rna transfection;block;as2o3-induced cell growth arrest;0;16283431
npdc-1 protein level;regulate;degradation;2;15229225
pathway rheb-target-of-rapamycin;regulate;process;0;17038544
npdc-1 activity;regulate;degradation;2;15229225
endogenous cdk1 expression;decrease;inhibition overexpression;0;21170085
endogenous cdk1 expression;decrease;inhibition increase;0;21170085
pathway s6k;regulate;process;0;17038544
ampk phosphorylation;increase;cardiomyocyte;0;23277190
camkius activation;mediate;ampk activation;2;23277190
day;inhibit;pgf;2;19403999
glucocorticoid receptor;mediate;effect;0;22832354
fenretinide;increase;testosterone;2;24241787
igf2;increase;estradiol progesterone production;0;17360960
datum;regulate;ape\ per ref -1 translocation;0;17599408
translation increase;block;s6k;2;20177060
cdx2;regulate;cell differentiation;0;19686845
ghrelin;increase;fast energy restriction;0;24760977
plc;activate;g protein g subunit;0;21906583
plc;activate;g protein g subunit;0;21906583
plc;activate;peptide g subunit;0;21906583
exogenous grk2;increase;growth factor receptor erk activation downstream;2;24018045
exogenous grk2;increase;egfr erk activation downstream;2;24018045
tumor suppressor pten;inhibit;cell pi3k signaling;0;25462559
gh ability;block;rapamycin;2;17284572
er;inhibit;cdx2 transcription;2;19686845
e2 protein;inhibit;luciferase gene expression;2;10982822
h4iie cell gh protein synthesis activation;inhibit;rapamycin;2;17284572
pregnancy day 16-18;inhibit;pgf;2;20431249
melatonin;increase;crop production;0;22016420
pregnancy;decrease;pgf;2;20431249
pregnancy;decrease;pgf;2;20431249
ghrelin arc pvn injection;increase;food intake;0;15817841
pregnancy;decrease;endometrium cell pgf synthesis;2;20431249
ghrelin;increase;rq;0;15817841
pregnancy;decrease;endometrium cell pgf expression;2;20431249
c-myc;increase;treatment;0;18697743105422191819697310723135108718541105789811297505114207041155564012172553123702901254378912747827126210621452741812954616152180331549902088876869695821102002801572810915797377159280811595205916305491164525011676485417041627171601371761343317616676176045971759651617804741179112671796280610660304
response;inhibit;rapamycin;2;18697743105422191819697310723135108718541105789811297505114207041155564012172553123702901254378912747827126210621452741812954616152180331549902088876869695821102002801572810915797377159280811595205916305491164525011676485417041627171601371761343317616676176045971759651617804741179112671796280610660304
result;regulate;c-myc;2;19332536108871501854206011046155112528931126821811296295114308251154417511864601120497391245342712883011136798531498292015197178197551381935309660782980906298379349858526100971421043090715522869158314611643222716673873167549551677483316880778169455521713609317136094168781581686217517272271175124021752533217597761179932391798686018079179185709611857977811018009
myc;upregulate;cancer;0;24705139
tumor suppressor p53;downregulate;expression;0;17001315
nine gene;regulate;p53 activity;2;1499079010473132103939351061870310677478109103641096471811016968110990281106991411684014117473201184032712399594124371201247739112526791125314731259026112843196128933661293232414514886702878818316921352858790951275660928543157864233790072329007243910229891533959153396928874095292489774969100651531022729310549356
hes1 hey1;activate;p53;2;1499079010473132103939351061870310677478109103641096471811016968110990281106991411684014117473201184032712399594124371201247739112526791125314731259026112843196128933661293232414514886702878818316921352858790951275660928543157864233790072329007243910229891533959153396928874095292489774969100651531022729310549356
finding;mediate;egfr signaling pathway;2;23178488120754021973710612670303127001211281425514522905146485881528933435195462253244829235676494778744354942620397969959923704155491071612086116456578169046691705115617118341174969231762264717611714202379632134622021402102219793072285478121129061108000921105789511121071113315801829558118275850186284011866942818985161191087131938324518832593192866641953302512174879
tfap4;activate;p53;2;1499079010473132103939351061870310677478109103641096471811016968110990281106991411684014117473201184032712399594124371201247739112526791125314731259026112843196128933661293232414514886702878818316921352858790951275660928543157864233790072329007243910229891533959153396928874095292489774969100651531022729310549356
p27 expression;increase;gastric cancer adenoma progression;0;10779641
cyclin d1 expression;decrease;tumor progression;0;10779641
datum;regulate;pp2a activity;0;20533062
datum;regulate;pp2a activity;0;20533062
c-myc p53 expression;increase;huh-7 cell;0;14745598
mkk4 form;inhibit;cd95-mediated jnk activation;0;11410864
mekk1;activate;pathway;0;10918063
mkk4 mkk7 jnk\ per sapk mkk3 mkk6 form co-expression;suppress;reporter gene expression;0;10918063
p38alpha form co-expression;suppress;reporter gene expression;0;10918063
pkcdelta\ per ras\ per mekk1 \ per mkk1-dependent\ per ap -1 pathway;regulate;sprr1b expression;0;10918063
mkk4;activate;jnk;0;17641059
mkk4;activate;mapk;0;17641059
cell proliferation activity decrease contrast;increase;development;0;11529881
histone acetylation;regulate;histone acetyltransferase;2;15476886
mdm2;regulate;p53 tumor suppressor;0;15734743
translocation;block;herbimycin;2;12112023
p14;regulate;activity;0;12869197
cortisol;downregulate;mammal;0;21887296106605511043867710802282110079011172891812052464124642401254129612746316129145321295997114500557145190988268474197146954501343651832803762521890240716721108531991808207400417784128432789822477880674517942157155279711548622615618479156184841570995915947887159470671637638416457828167630831690199017535883175358841763446217641289174703711768999618096659182399791825868218931045190739031944808321451143178485598984741952533310674279
cortisol;downregulate;level;0;21887296106605511043867710802282110079011172891812052464124642401254129612746316129145321295997114500557145190988268474197146954501343651832803762521890240716721108531991808207400417784128432789822477880674517942157155279711548622615618479156184841570995915947887159470671637638416457828167630831690199017535883175358841763446217641289174703711768999618096659182399791825868218931045190739031944808321451143178485598984741952533310674279
myc;activate;transcription;0;16316993
erk;regulate;apoptosis;0;15672448
therapy;inhibit;protein;0;18483317
therapy;inhibit;pathway;0;18483317
tmp;block;erk;2;23247439
tmp;activate;p53;2;23247439
tmp;activate;p53;2;23247439
n-myc;regulate;pattern formation;0;21562282
contrast;inhibit;condition;0;2146080421394080
cdk6;downregulate;treatment;0;2226618723235255
protein degradation;mediate;ubiquitin;0;11311237
protein degradation;mediate;ub;0;11311237
irradiation;activate;p53;2;14712074
latter;activate;erk kinase;2;25145835
tgf-beta;inhibit;cell proliferation;0;15333329
tgf-beta;inhibit;enzyme activity;0;15333329
tgf-beta;inhibit;phosphorylation;0;15333329
tgf-beta;increase;p15;0;15333329
activation;inhibit;mek;2;11274363105938831033017010713157108112241090866811032806110739402831066850637679920577759517764652885520718617871866280390025219069255909633691620929177222930563893548119384583938458495164389535930961850797120469759885979019498519329886415989095199734821018780410669751
study;regulate;hepatocellular carcinoma;2;22228088
p21;regulate;cell cycle;0;15947694
p27;regulate;cell cycle;0;15947694
contrast;decrease;proliferation;0;15544931
estrogen receptor;regulate;gene transcription;0;244410412211707921779010212235692168053822427816227118542290263822863777230008971090865511329139123344911183958012526785126674521509374324259421603713216636675170065371714534517440111173675451754563418344977183850391838815019136968192375371970124219801972199201891988764720103625200201972107803921305704214551802145518121356307
arf;regulate;mdm2;2;16491126
chk1;upregulate;carcinoma;2;15707569
tumor suppressor p53;downregulate;expression;0;17001315
model;regulate;cyclin d1;2;21779442100759289199319103856181053100510934345111248031154417511850621123868171242990912429916126486711451729715190204152209311528982515475007154966571559250715735756158768751613801016393691167748331694262216969133181634641827757184140281860678319291319293801638608683918269789893779588448108113838937884913788524413860801486290238636218893966889398499136925937296798325039925749941787520506465862485110373511
dopamine;inhibit;activity;0;19020776
p53;mediate;apoptosis;0;1823159417081985164554861072274211080164110940891126525011593407115728691222665712620801127197151291763614730303152426461528037720057818479525825203782934687838736948866115661530161480071628845910535925
bmal1;regulate;feedback;0;25369242
astemizole ezh2-eed interaction disruption;inhibit;activity;0;25369470
interleukin-6 concentration;increase;significance melatonin application;2;25350595
interleukin-6 concentration;increase;361.32 235.22 pg\/ml 262.58 233.92 pg\/ml melatonin application;2;25350595
fosl2 expression;regulate;tgf;2;25375657
protein;regulate;erk function;2;25375375
erk sustained activation;inhibit;autophagy process maturation step;0;25375375
bmal1;regulate;feedback;0;25369242
interleukin-6 concentration;increase;significance melatonin application;2;25350595
interleukin-6 concentration;increase;361.32 235.22 pg\/ml 262.58 233.92 pg\/ml melatonin application;2;25350595
arctigenin;inhibit;ar protein expression;0;25380086
combination treatment;inhibit;ar pi3k\/akt pathway;2;25380086
proanthocyanidin;mediate;collagen cross-linking;2;25379878
pac;mediate;collagen cross-linking;2;25379878
proanthocyanidin;enhance;dentin collagen base tissue property;2;25379878
pac;enhance;dentin collagen base tissue property;2;25379878
pac;decrease;collagen digestion;2;25379878
pai-1;inhibit;vegfr-2 binding;2;25378411
pai-1;inhibit;vegfr-2 binding;2;25378411
t. matsutake mycelium extract;decrease;activity;0;25319362
tropoelastin expression;increase;fibroblast;0;25319362
mmp-1 induction t. matsutake mycelium extract effect;mediate;fibroblast p38 inhibition;0;25319362
mycosporine-gly treatment;increase;skin inflammation response;0;253175351356394154804871275213712661961125883831123363824374576223618572216384721672617974572921556168211906742061724920479978203626922045466915986833161510801635469516583025166729631797028118157682184744601869756518312388
sesn3;activate;mtorc2;2;25377878
elastin;regulate;pre-stretch;0;25301303
klotho expression;decrease;glucose tolerance;2;25377875
addition;suppress;foxo1 phosphorylation;2;25377663
klotho protein administration;suppress;foxo1 phosphorylation;2;25377663
addition;suppress;akt phosphorylation;2;25377663
klotho protein administration;suppress;akt phosphorylation;2;25377663
icariin;suppress;bone degradation;2;25374443
ape;decrease;tgf 1 elevation;2;25373883
2.6 5.2;decrease;tgf 1 elevation;2;25373883
ape;decrease;collagen i elevation;2;25373883
2.6 5.2;decrease;collagen i elevation;2;25373883
ape;decrease;collagen iii expression elevation;2;25373883
2.6 5.2;decrease;collagen iii expression elevation;2;25373883
ape action mechanism;decrease;tgf 1 level;2;25373883
ape action mechanism;block;tgf \/ smad signaling pathway;2;25373883
response cox-2 activation;mediate;pik3\/akt pathway;2;25371970
28 day rat mc fruit extract administration;decrease;fast blood glucose level;2;25371774
28 day rat 1.5 body weight administration;decrease;fast blood glucose level;2;25371774
niacin;activate;pi3k\/akt;2;25375133
carcinogenesis process;regulate;antioxidant enzyme;0;25225603
carcinogenesis process;regulate;antioxidant enzyme;0;25225603
carcinogenesis process;regulate;enzyme;0;25225603
carcinogenesis process;regulate;enzyme;0;25225603
bxpc3 tumor cell tgfbus addition;inhibit;growth;0;25369402
bxpc3 tumor cell tgfbus addition;inhibit;migration;0;25369402
procedure;increase;collagen synthesis;2;25367711
atorvastatin;increase;bax reaction intensity;2;25366571
100 etoh myocyte incubation;decrease;elastin;2;25142777
100 etoh myocyte incubation;decrease;increase collagen content;2;25142777
ampk inhibitor compound c;block;collagen stimulation;0;25142777
ampk inhibitor compound c;block;adamts1 protein stimulation;0;25142777
phosphatase;enhance;pi3k\/akt signal pathway;2;25364523
tensin homolog;enhance;pi3k\/akt signal pathway;2;25364523
pten;enhance;pi3k\/akt signal pathway;2;25364523
activity;enhance;pi3k\/akt signal pathway;2;25364523
rgs5 deficiency;decrease;collagen content;2;25363362
gen;block;tak1\/mkk4\/jnk pathway;2;25362897
collagen;increase;three model alveolar airway wall;0;25106431
datum;decrease;permeation;0;25068721229522182133863523391444235241882377021311063882111563951293263517373518323940817412679717218744570927804696660881592198016023192160237531621153816919353172920791756955419324684199025272038518523036225
inflammation;enhance;matrix degradation;2;25067996
adam9;regulate;collagen accumulation;2;25063875
conclusion;inhibit;pi3k\/akt pathway;2;25356754
emilin1 deficiency;mediate;mapk\/phosphorylated erk1;2;2505670020576933202996902116326420809794210756492194941222007101220348902187145822265892226395472259599022827975229406052291764423162011236373352451304011028464115839611208214312142029124442021247564412952829147017371521790615473488567073671878263739919376914917323538425319904406895932041554600415632106158270621595613816530041166451421698011616973908172934781839082018955677190650031936313619584318196272671966146319647408199226302020190121133377
emilin1 deficiency;mediate;erk2;2;2505670020576933202996902116326420809794210756492194941222007101220348902187145822265892226395472259599022827975229406052291764423162011236373352451304011028464115839611208214312142029124442021247564412952829147017371521790615473488567073671878263739919376914917323538425319904406895932041554600415632106158270621595613816530041166451421698011616973908172934781839082018955677190650031936313619584318196272671966146319647408199226302020190121133377
emilin1 deficiency;mediate;tgf;2;2505670020576933202996902116326420809794210756492194941222007101220348902187145822265892226395472259599022827975229406052291764423162011236373352451304011028464115839611208214312142029124442021247564412952829147017371521790615473488567073671878263739919376914917323538425319904406895932041554600415632106158270621595613816530041166451421698011616973908172934781839082018955677190650031936313619584318196272671966146319647408199226302020190121133377
disease;mediate;mapk\/phosphorylated erk1;2;2505670020576933202996902116326420809794210756492194941222007101220348902187145822265892226395472259599022827975229406052291764423162011236373352451304011028464115839611208214312142029124442021247564412952829147017371521790615473488567073671878263739919376914917323538425319904406895932041554600415632106158270621595613816530041166451421698011616973908172934781839082018955677190650031936313619584318196272671966146319647408199226302020190121133377
disease;mediate;erk2;2;2505670020576933202996902116326420809794210756492194941222007101220348902187145822265892226395472259599022827975229406052291764423162011236373352451304011028464115839611208214312142029124442021247564412952829147017371521790615473488567073671878263739919376914917323538425319904406895932041554600415632106158270621595613816530041166451421698011616973908172934781839082018955677190650031936313619584318196272671966146319647408199226302020190121133377
disease;mediate;tgf;2;2505670020576933202996902116326420809794210756492194941222007101220348902187145822265892226395472259599022827975229406052291764423162011236373352451304011028464115839611208214312142029124442021247564412952829147017371521790615473488567073671878263739919376914917323538425319904406895932041554600415632106158270621595613816530041166451421698011616973908172934781839082018955677190650031936313619584318196272671966146319647408199226302020190121133377
research;increase;health care service use;0;25368165
research;enhance;life quality;0;25368165
type i collagen expression;increase;concentration manner;0;25352963
tgf expression;increase;emd 100 g\/ml;0;25352963
lung septation defect;decrease;tgf 2 level;2;24962333
addition;upregulate;ctgf expression;2;25351242
visfatin concentration hsc treatment;upregulate;ctgf expression;2;25351242
collagen secretion;decrease;a549 culture medium ls-102 synoviolin inhibitor addition;0;25351210
hyperhomocysteinemia;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
hhcy;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
vegf;activate;anti-neovascularization mechanism;0;25349789
dn cell;activate;collagen transcription;2;25349198
dn mouse kidney;activate;collagen transcription;2;25349198
salum;inhibit;elastin fragmentation;2;24916705
glucose;decrease;mmp-1 expression;0;24904926
polypeptide synb1-elp-pkus;inhibit;pka activity;2;24903464
polypeptide synb1-elp-pkus;inhibit;pka activity;2;24903464
lox expression;upregulate;belomycin;2;25348956
hhcy;increase;elastin;2;24896329
hhcy;increase;collagen deposition;2;24896329
mouse diet sulforaphane;increase;ex vivo adhesion;0;24880493
mouse diet sulforaphane;increase;ex vivo adhesion;0;24880493
protein therapeutics;increase;number;0;24871936
protein therapeutics;increase;frequency;0;24871936
cse;increase;ecm molecule collagen i collagen iii fibronectin cell proliferation;2;25344066
cse;increase;ecm molecule collagen i collagen iii fibronectin deposition;2;25344066
active;enhance;therapeutics accumulation;2;24856169
collagen cross-linking;decrease;kc progression;0;25343263
caffeine;inhibit;collagen biosynthesis;2;2534288512960921174888045432063432385471399612213589860379016709440174087001756747424275088178041111789931618491034183202911911499019427585195137552280947115164313
concomitantly;increase;polymerase activity;2;25361036
adipose tissue fibrosis;increase;at rigidity;0;25337653
testosterone;decrease;age;0;25360023
hsya treatment;decrease;collagen synthesis amount;2;2533721817433563176788831767862917941891190840791918882819224893197006472056450721508343216772952219782523275087245481862512077211448960117392751200385512567893126447241282919216639718601637158945331608763516113066165568681714118318060181
trophic unit elastin change remodel;dysregulate;disease pathology;0;24747433
trophic unit collagen change remodel;dysregulate;disease pathology;0;24747433
mycose case;increase;year;0;25358415
fl772;inhibit;yeast cell s6k phosphorylation;2;25356520
muscle cell phenotype control;regulate;tgf activation;2;24679588
muscle cell phenotype control;regulate;tgf availability;2;24679588
synthesis;increase;elastin gene;2;24670922
collagen fluorescence intensity;increase;dadsc adsc group;0;2466416719072088200138482013137020568271206797262083075920528146213914252128756221858450219592382168906222359557225656362303153123197781233726962411502511304456118003741267141712903682146533581557778216425555165147971667682516826069171410881740974617895858182374941798998819089456
collagen increase;increase;session number;0;24641603
decrease elastin content increase;increase;session number;0;24641603
infarct;increase;patient;0;25352047
elastin content;decrease;age;0;2456157924637262
iium fibroblast treatment;up-regulate;67-kda elastin protein production;2;24525372
liver;mediate;degradation;2;24504736
elastin secretion;decrease;6 month;0;24503000
class ii fibromodulin decorin class i member;regulate;collagen fibrillogenesis;2;24443020
class ii fibromodulin decorin ii member;regulate;collagen fibrillogenesis;2;24443020
class ii fibromodulin biglycan class i member;regulate;collagen fibrillogenesis;2;24443020
class ii fibromodulin biglycan ii member;regulate;collagen fibrillogenesis;2;24443020
lung fibroblast;increase;elastin type v collagen tenascin c. gene expression;2;24291458
6;inhibit;cell survival migration mt1-mmp expression;2;24194191161234001589978416306453163716001655752017308049176027101807434918708613200212542104129822232368221780792159386222512648105481141071312610742145109981351144896411778052120821431254375412682293127781321284208712858548149847641516182310190567107897621607024253252455830904626515632016156321061578132216151532
iv;inhibit;cell survival migration mt1-mmp expression;2;24194191161234001589978416306453163716001655752017308049176027101807434918708613200212542104129822232368221780792159386222512648105481141071312610742145109981351144896411778052120821431254375412682293127781321284208712858548149847641516182310190567107897621607024253252455830904626515632016156321061578132216151532
6;inhibit;mcec fak\/pi -3 k\/mtor\/akt phosphorylation;2;24194191161234001589978416306453163716001655752017308049176027101807434918708613200212542104129822232368221780792159386222512648105481141071312610742145109981351144896411778052120821431254375412682293127781321284208712858548149847641516182310190567107897621607024253252455830904626515632016156321061578132216151532
iv;inhibit;mcec fak\/pi -3 k\/mtor\/akt phosphorylation;2;24194191161234001589978416306453163716001655752017308049176027101807434918708613200212542104129822232368221780792159386222512648105481141071312610742145109981351144896411778052120821431254375412682293127781321284208712858548149847641516182310190567107897621607024253252455830904626515632016156321061578132216151532
ear cartilage chondrocyte culture ltbp-2 addition;block;elastinogenesis;2;24148803
ctgf;regulate;ecm deposit;0;24052232
adv-ctgf;enhance;ctgf expression;0;24052232
adv-ctgf;enhance;fibronectin expression;0;24052232
adv-ctgf;enhance;collagen iv expression;2;24052232
rofecoxib;inhibit;rat aorta elastin cross-linkage formation;2;24025789
junction opener intravenous injection;increase;antibody chemotherapeutic therapy efficacy;2;23898462
junction opener intravenous injection;increase;antibody chemotherapeutic therapy safety;2;23898462
junction opener intravenous injection;increase;mouse tumor model cell therapy efficacy;2;23898462
junction opener intravenous injection;increase;mouse tumor model cell therapy safety;2;23898462
o2 treatment;downregulate;type i collagen ecm molecule expression;2;23815460
o2 treatment;downregulate;elastin ecm molecule expression;2;23815460
tgf r2 alveolar expression;decrease;75 %;0;23711546
study;increase;plaque component know datum range;2;23683797
collagen;enhance;interaction;0;23625321
substance;inhibit;glycoxidation;2;23612546
tropoelastin pre-incubation;increase;mmp-2 production;0;23597635
melanin;increase;collagen;2;23579949
melanin;increase;elastin;2;23579949
elastin content;decrease;increase elastase concentration treatment time;0;2355382715868802962825417343278177622891973370419900677206385232146655121874555111652841174467911871607120821433682546478829384506038138476965197337908220603097809748921831017428205940728313572315137107571560787710412460
ctgf;mediate;remodel;0;23527070174787301749812218694554187723281930125919451413195159341955350119729479194076552015372220560046206438282069331721248169211219852105014021856305219409492203754922258897217299922222720722398634224068212271848110562268107164701087919711730097117794581188061611773059128445131461391515219813193434385052948342638158832131584588615911744160209131608419816322555168401731701530018460596
collagen elastin content;decrease;four decellularization condition time;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image ic ratio;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image r;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image shg;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image skew;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
has-2 tropoelastin mmp-1 hgf expression;increase;gm-csf;0;2337269611075003159074421200289312184584124096761267141712843410145139601682606917069015172142681751867318357839184444841848081219041509190330791921303919374154200825712071509120516667209626432155724520926197223595391509123324647677683465751042389034511582556611391249
elastin;regulate;transduction response;0;23355960
collagen waviness;decrease;degradation time;0;232970001516586912730082457696495769683330563227266331204364923628268278028090967465698051981579634016055757160065411588569916849214164884771725458917237244186471151865781319230148191598871932440719394942194843872008076620583273203547532065992821375736215991002105802521724865217300372223653221744269221892492230529015057970221710632262310910633258110365551145174912093072128375796075755
cell therapy group;decrease;aneurysm formation rate;0;23291168
surface elastin;enhance;chondrocyte biocompatibility;0;23261552
artery;decrease;elastin content increase k s activity;2;23180031
vegf;increase;lox activity;0;22966818
vegf;increase;expression;0;22966818
matrix metalloprotease;increase;glucose concentration increase;2;22966818
mmp;increase;glucose concentration increase;2;22966818
activity;increase;glucose concentration increase;2;22966818
corticosteroid posttreatment;decrease;collagen type;2;2296201016770071163443331700023517071719172933751817777817965320182640251872710518657064191102331924460418552709193012441950229119860666200223152009364620861353208212302093522820959141210547592068886721257142211101161082176710926289110996031110254711416869115879832189051122147379221642192216030622302193118466091211420812151307126295531266783112671110128392903982875826951879008318764225900606794284239731532976836310419836154479371581749916856047
agldl;increase;degradation rate;2;22947869102169591987988155503961687898617353438182309561849368019251640192290591950156419603496206749692071308120665685213050182150974321798376221050952216977311226511151326871514868610666072108458741098167511884279121216541247355912639996126008861278510520220282022748168032419108051911707177796316066641466664825144681550897488140759281175862228645189910615797123269874220151235726074050484758144725301773787213035354153935593792648148277528110398014
tract symptom therapy;inhibit;muscle contraction;0;229066511793411721324841472097348206494787928483755387400221575876416021508164091451713039317299435175186291752524921231991181617451816490718227479183421901834341418554695193470141935589519539753197829461967024219690397199421582359465923261478
treatment;increase;collagen type iii;2;22853187
mmc treatment;decrease;collagen elastin fiber amount;2;22828051
angiotensin ii;enhance;collagen;2;228176061988122618495696220401462160607611121512105780021072528010988257115329011171150612364350123643541254445112560337128295221467825114718399150761591509723618594792192622271938061019451411197240241516600981872808978321104758881568783815547110156555301610325816043661162310031714598017572703181720551822748120649560
topography;upregulate;artery muscle cell synthesis;0;22796164
topography;upregulate;hcasmc synthesis;0;22796164
adhesion protein;downregulate;3d scaffold topography;2;22796164
efficiency;decrease;increase collagen content;2;22750739
estrogen;activate;collagen fiber synthesis;2;22727818
study;secrete;elastin;2;22718481
hf;down-regulate;collagen gene expression;2;2250738123821792
hf;down-regulate;elastin gene expression;2;2250738123821792
elastin degradation;mediate;metalloproteinase protease;0;22411928
diabetic rat;decrease;corpus cavernosum muscle\/collagen ratio;2;22403279
ica ii;regulate;tgf 1 \/;2;22403279
degradation phenomenon;enhance;vivo;0;22349289
tgf;mediate;differentiation growth event;0;22335518
tgf;mediate;differentiation development event;0;22335518
tgf;mediate;proliferation growth event;0;22335518
tgf;mediate;proliferation development event;0;22335518
tgf;mediate;motility growth event;0;22335518
tgf;mediate;motility development event;0;22335518
tgf;mediate;organization growth event;0;22335518
tgf;mediate;organization development event;0;22335518
tgf;mediate;death growth event;0;22335518
tgf;mediate;death development event;0;22335518
tgf binding;regulate;target gene transcription;0;22335518
hmfc;increase;collagen type;2;22281808
hmfc;increase;collagen type;2;22281808
hmfc;increase;collagen type;2;22281808
hmfc;increase;collagen type;2;22281808
glycation;increase;collagen intensity;2;22277703
insulin concentration;up-regulate;collagen type;2;22236491
insulin effect;activate;gene transcription;0;22236491
tropoelastin expression;increase;injury duration;0;222231972342400823424101
macrophage;increase;elastin;2;222231972342400823424101
mmp-12;regulate;degradation;2;222231972342400823424101
collagen content;increase;zl zdf rat;0;2200823616901964170830711732474618195160204828732055067819696142206645442115101321771972216730481080360211040225113276401186325211897758123643541238445712414524124510131238831412574082126707501267585512679215126820821279909912782645147617801511791382282029453344159928191650520816636193
exosite 1 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
2 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
site one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
exosite 1 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
2 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
site one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
exosite 1 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
2 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
site one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
combination mutant asp124;enhance;elastin k;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
combination mutant asp124;enhance;elastin cat;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
synb1-elp-trtk peptide;decrease;s100b-induced oxidative damage;2;2195886416919353171618271748335617417937177260191791384317762916184949331845218418418661190564201909502019351032191100111951300119593677196379801974389519898461197054612003398320053360201327952016723911549583117246071247095512645009128932741289341615098935151112351054592010679531107275121110618011007787112454641132571311390274151989872529544259241421503201769063820249375401767606463755385488988639439795103959341559006715814459158955631602066520632605204779102081837921080947204783482138419520938714161715561701045517143231
fibrillar collagen;regulate;soxe gene;0;21889937
collagen i transcription;increase;raise scar tissue;0;21838832
collagen i translation;increase;raise scar tissue;0;21838832
nir irradiation;increase;elastin;2;21833163118096480433841456883016875471194386882052390821408032215593198188885153815551554554016049894167067531691856116941737173005991745776418306155192713671966310719812595203454842136935912512648
antihypertensive therapy;decrease;wall hypertrophy;0;21829037
antihypertensive therapy;decrease;collagen;2;21829037
age;decrease;matrix component collagen fiber synthesis;2;2182615310652273115572821171093611869737118865091223051212437452128095541438199147326401496553150362691768990518028961093209312217862125158651274217015175039153313991771153217957138190468301964151823425781548906086581963456347347030835219883534809362851070355327216901779861779049028125163820691982944688332640890147089348788962489899480890247019442117946248315623355167237011687735016987749172009429117985985682816405877176317831096213410974019111524691132008311399545192963041936196198842792030266203996142049064210468021123617242465424740282577359267422410085121100926501022215310506580
age;decrease;matrix component collagen fiber degradation;2;2182615310652273115572821171093611869737118865091223051212437452128095541438199147326401496553150362691768990518028961093209312217862125158651274217015175039153313991771153217957138190468301964151823425781548906086581963456347347030835219883534809362851070355327216901779861779049028125163820691982944688332640890147089348788962489899480890247019442117946248315623355167237011687735016987749172009429117985985682816405877176317831096213410974019111524691132008311399545192963041936196198842792030266203996142049064210468021123617242465424740282577359267422410085121100926501022215310506580
collagen iv labeling;decrease;media;0;21824826
collagen iv labeling;decrease;adventitium;0;21824826
elastin;decrease;hhcy avf heart;0;2176096989289147890717942051995086510763084115009251189355212106681956224715992576160856801617212016195484162841821645080716464240171785941850424199135853354423543206378677647878023123499021273006214639017149755731563745315975610164610511651466521076854222297723641364810564100821971018833410524225105457741060644110694530111134581116973511179202112895021146175211863251119011821204516312076971121141841215410312388235145568521473275215047687151178451520517415217918156817081582183315851618810768983209678796111
akt pi3k activation inhibitor;block;type i collagen expression;0;2175121112681450146100661470234415056658565640291593742608030570719169425983793610446062155396341568182115807523157314941581483716227992168376501687082717209135172123591749393117607364176225101817203719779471
thiosulfate;inhibit;seed crystal formation;2;217375161515355015168392513482388622630088221587021819369406165319811798965018818688190089091912979316191185
thiosulfate;inhibit;elastin calcification formation;2;217375161515355015168392513482388622630088221587021819369406165319811798965018818688190089091912979316191185
tgf;increase;collagen production;2;213842001693068616877348174351081757978617887902105737751099242711176523113719521218710412757606126655341476734615117886152074642883922975140610192538104583911553505815467014154920091843036918279932186227031769092918406048196250421962505119831488161339161603887719569874163604821664349817293495
1;increase;collagen production;2;213842001693068616877348174351081757978617887902105737751099242711176523113719521218710412757606126655341476734615117886152074642883922975140610192538104583911553505815467014154920091843036918279932186227031769092918406048196250421962505119831488161339161603887719569874163604821664349817293495
iugr;decrease;birth elastin fiber formation transcript level;2;213639671297063012869365126828491463098415116139151728961517289735317622679260220654019909592002279767821882140898279570770075477974688929856908892391313189201877937439294588009585000964909310051278102107061551666416002560163968751638040716617452167239791672073216921131170653711714234917293375174288971822826518187616183888111821606318482625191444031951405920130146202272022009364620382748205252052086982010832740109708221109960311117232115364491164145511846609120723781212183712388463
iugr;decrease;day 7 elastin fiber formation transcript level;2;213639671297063012869365126828491463098415116139151728961517289735317622679260220654019909592002279767821882140898279570770075477974688929856908892391313189201877937439294588009585000964909310051278102107061551666416002560163968751638040716617452167239791672073216921131170653711714234917293375174288971822826518187616183888111821606318482625191444031951405920130146202272022009364620382748205252052086982010832740109708221109960311117232115364491164145511846609120723781212183712388463
study objective;increase;elastin synthesis;2;2128261810201117870263910404017104713179104703943841018849207188473641981321919962188197120461649108716674303165669111734512317584900180354121833883018412137179690241059023610870892120428651208214312684159129358181459775514704646153062281288208227136853199710205057
cd4 cd4\/cd25 lymphocyte;increase;thymus lymph node;0;21257142
pup lung;increase;elastin deposition;2;21239531
adenine dinucleotide nicotinamide biotin link number;mediate;sir2\/sirt1 activation;2;25349818
metabolite link number;mediate;sir2\/sirt1 activation;2;25349818
glucose level;increase;4v 3hb injection;0;21358145
reinforcement;mediate;forebrain increase dopamine level;2;25374094
cocaine;increase;area 1 mechanism rat dopaminergic neuron pacemaker burst firing frequency;2;25374094
increase muscle capillarization;increase;insulin sensitivity;2;25352432
muscle glucose uptake;enhance;muscle insulin improvement;0;25352432
adrenaline effect;block;nicergoline;0;25272708
adrenaline effect;block;10;0;25272708
adrenaline effect;block;-6;0;25272708
adrenaline effect;block;increase obzidan;0;25272708
adrenaline effect;block;10;0;25272708
adrenaline effect;block;-6;0;25272708
amygdalum dopaminergic innervation;regulate;behavior;0;25018040
amygdalum dopaminergic innervation;regulate;stress responsivity;0;25018040
study;inhibit;vegf;2;2495273221035837218931932213023123172303105440021094965511062485113507301180971511912249123602821257687112771931128149521294901114660505151632731510781815294883137593182614528616842882220591094859210714935268696174809823983105100031639726216775835168397451699059818288940
result;inhibit;akt;2;2495273221035837218931932213023123172303105440021094965511062485113507301180971511912249123602821257687112771931128149521294901114660505151632731510781815294883137593182614528616842882220591094859210714935268696174809823983105100031639726216775835168397451699059818288940
cockerel food intake ghrelin effect;mediate;2 receptor;0;25080314
hypertension;increase;akt phosphorylation;2;24933619
dopaminergic system;regulate;blood pressure;0;24500688
sirt1;activate;restriction response;0;25109279
sirt1;regulate;hormone role;0;25109279
egfr stimulation flj00018 phosphorylation;mediate;protein kinase;0;24554703
egfr stimulation flj00018 phosphorylation;mediate;mapk;0;24554703
egfr stimulation flj00018 phosphorylation;mediate;pathway;0;24554703
roflumilast;suppress;collagen matrix protein stress;2;25035926
roflumilast;suppress;collagen matrix protein deposition;2;25035926
isoproterenol;activate;erk;2;24151242
iso;activate;erk;2;24151242
carvedilol;activate;erk;2;24151242
mat;increase;human cancer therapy;2;24998914
adiponectin;increase;human cancer therapy;0;24998914
forskolin;enhance;patch pipette solution pka subunit synthesis;2;23587884205905992071667121130951170209341744889218006481211353612122827221454534214778712173781821856484220344802215999322354969224338602248433123040838229554901182768611850507119769391200752812650866126508671256033714522815258114326073331326051786492278640751612512416123335164038371062530310950925115025841899069819542013198189461911991620194511753998987600438819531886506710484333158243091581763216002746
forskolin;enhance;patch pipette solution pka subunit inclusion;2;23587884205905992071667121130951170209341744889218006481211353612122827221454534214778712173781821856484220344802215999322354969224338602248433123040838229554901182768611850507119769391200752812650866126508671256033714522815258114326073331326051786492278640751612512416123335164038371062530310950925115025841899069819542013198189461911991620194511753998987600438819531886506710484333158243091581763216002746
inhibitor leptomycin b;inhibit;1-ar signaling;0;22120526175066391744048418552157188020281923457418989658192819132046303020628612207324142107904111264479127826801275626012888550146456681471553214736874152079001521328977303637559466942143595724969852141160027451610983616195468165859651663162816574786169025761692930517172694172832561731777018437627
lh tem;decrease;epidermis thickness;0;24894526
lh tem;decrease;area;0;24894526
epinephrine tourniquet use;decrease;blood loss;0;21131843
epinephrine tumescence;decrease;blood loss;0;21131843
study;regulate;ghrelin synthesis;2;22691550
seek reinstatement clonidine effect;mediate;sedation;2;208548301553649315765262120975231222353892182769292629935312894287629471114949702210208381102290651039500015266350162693171707966016893525175618241750501817976662181544981828103319006007105417291059188010651884108828401092376010936169110158001125592711714880117409511179705611817765118623741204698212696841127241591278037312402102128576621287229015065954152243841538037449364581228825627625456429747075872919986171630720024619217073203577602061371861290326822957619114263242066204716298190628649702997411372966724284392900154245955231770692571277259491323730701678707142108618427021480352838356682638117903902798206277246977659764767597074750348821441884199088879768946419
seek reinstatement dexmedetomidine effect;mediate;sedation;2;208548301553649315765262120975231222353892182769292629935312894287629471114949702210208381102290651039500015266350162693171707966016893525175618241750501817976662181544981828103319006007105417291059188010651884108828401092376010936169110158001125592711714880117409511179705611817765118623741204698212696841127241591278037312402102128576621287229015065954152243841538037449364581228825627625456429747075872919986171630720024619217073203577602061371861290326822957619114263242066204716298190628649702997411372966724284392900154245955231770692571277259491323730701678707142108618427021480352838356682638117903902798206277246977659764767597074750348821441884199088879768946419
1ar cell gfp-arrestin-3 co-expression;increase;1ar endocytosis;0;22378779112079431122625911343413112792031154680512411301128780041282166012888573129471041461549314734649793581586930011037737815331590164842241737964617521381179954501819498918434512193424481960220421041313206546912154018921680031105955211072041011150299
1ar cell gfp-arrestin-3 co-expression;inhibit;recycle;0;22378779112079431122625911343413112792031154680512411301128780041282166012888573129471041461549314734649793581586930011037737815331590164842241737964617521381179954501819498918434512193424481960220421041313206546912154018921680031105955211072041011150299
phentolamine;suppress;pkc translocation;2;19695215
pd98059 pretreatment;inhibit;rbmsc erk1\/2 phosphorylation;2;19695215
adrenaline;upregulate;abcb1 gene expression;0;19380024
norepinephrine;regulate;function;0;2114360088667038982161920491792189769329158160507781633622616772391168969481687698218537547186511751892413919068224188116781942946319442879193320371983310419883653202362212057389420837485106276041073410710999947183812842319246286893622085261332297184321308192430080413017510187070183814448478697768946679074318083758112481161140442511750876117420701194387812194863123704251282346512832552127682741506309915128846152822676036174168592437776186982163721724113217164822174163541713955917702867174882771785560817896981181843131848261093905179515967955177296634459739125157990101590178915982754
tumor suppressor protein p53 inhibitor;block;apoptosis;0;18628404
p53 translocation;block;prazosin bmy 7378 apocynin sb 202190;0;18628404
p53 translocation;block;pifithrin-alpha;0;18628404
estrogen;increase;fgf21 production;0;24634829
norepinephrine;increase;number mtt uptake;0;18441198151594031504403515494560714433125632862566608134663513500951452288129164881064227814630775870788480158813557932301394093079721723981513198224499856972103817561038426210452527105065541554883015711063158492361604028116266318163311111634437416394249164066801656544016566918167332281668250516908950103862521690217816679391170736131741645817459951175251611762028416139252106267541107869611518777118569131243714212563019126239981294398914656924147419091476981015311997
norepinephrine;increase;3h;0;18441198151594031504403515494560714433125632862566608134663513500951452288129164881064227814630775870788480158813557932301394093079721723981513198224499856972103817561038426210452527105065541554883015711063158492361604028116266318163311111634437416394249164066801656544016566918167332281668250516908950103862521690217816679391170736131741645817459951175251611762028416139252106267541107869611518777118569131243714212563019126239981294398914656924147419091476981015311997
norepinephrine;increase;rat aortic vsmc receptor incorporation;0;18441198151594031504403515494560714433125632862566608134663513500951452288129164881064227814630775870788480158813557932301394093079721723981513198224499856972103817561038426210452527105065541554883015711063158492361604028116266318163311111634437416394249164066801656544016566918167332281668250516908950103862521690217816679391170736131741645817459951175251611762028416139252106267541107869611518777118569131243714212563019126239981294398914656924147419091476981015311997
heart half-life;increase;rapamycin;2;24612461
5-methylurapidil;inhibit;contraction;0;18430422
author;activate;sirt1;2;24606795
receptor;activate;mechanism erk;2;19037712
clozapine;increase;blood glucose;2;17629416
clozapine;increase;insulin;2;17629416
dopamine;regulate;phagocytosis;0;17574246
prazosin;inhibit;erk activation;2;17306214
gf109203x;inhibit;erk activation;2;17306214
pathway absence;activate;erk;2;17283256
rolipram pde4 inhibition;enhance;camp accumulation pka phosphorylation contraction response;2;187036691127371610862778115028901180458811872839121306681089908318045878123995921255209712493749127919801517863874768868663227933721615644445157178661578848916246108166420351669705516856846168090661690565117038640168995511742822817431197173760271761537117663574180562631818815411358334
pka activity;enhance;10 isoproterenol -lrb-1-rrb- activation;0;187036691127371610862778115028901180458811872839121306681089908318045878123995921255209712493749127919801517863874768868663227933721615644445157178661578848916246108166420351669705516856846168090661690565117038640168995511742822817431197173760271761537117663574180562631818815411358334
sirt1 4 expression;increase;cr group;0;24535021
sirt1 4 protein expression;increase;cr group rat tissue;0;24535021
akt activation;block;machinery inhibition;0;18194989107482141037737817305471174469301566834211006286111810231134341311259422116045491153305611909972150312611653274134764183934938119963105359611066275510720410107539431079952981566008160017774481177618547629102938825594054629618528973801410089883103395991035983818281371
dn akt;block;hypertrophy;0;18194989107482141037737817305471174469301566834211006286111810231134341311259422116045491153305611909972150312611653274134764183934938119963105359611066275510720410107539431079952981566008160017774481177618547629102938825594054629618528973801410089883103395991035983818281371
plc isozyme;regulate;gene expression;0;16714034
food restriction;mediate;glucocorticoid;2;24477541
mfr;mediate;glucocorticoid;2;24477541
stress;mediate;glucocorticoid;2;24477541
beta -lrb-1-rrb- ar erk stimulation extent;enhance;-lrb-1-rrb- ar-autoantibody presence;0;1762851417707357
beta -lrb-1-rrb- ar erk stimulation extent;enhance;isoproterenol presence;0;1762851417707357
anisomycin;block;step expression increase;0;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
mapk\/erk kinase application;block;perk activation;0;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
mek application;block;perk activation;2;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
inhibitor application;block;perk activation;2;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
sl327 application;block;perk activation;2;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
mapk\/erk kinase application;block;step translation activation;0;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
mek application;block;step translation activation;0;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
mtor inhibitor;block;step translation;0;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
rapamycin inhibitor;block;step translation;0;17623046104149901525421411739565117566821188048311799119119317471198071111983687152542171538125515755733158001841544767916000624159085121602511116891611169347531067045810683568109086001093423910964936112975051158406911551908154501611548703129882614075150287697328299953390719165023383313847935815786911685966558785058878995689878109363896942271797547929856468103717111248321512764105128907681293728614722243150163801506628815152046152522801525409115591229
rat cord preparation noradrenaline rhythm facilitation;mediate;receptor;0;16412573
contrast;increase;reperfusion 2 min;0;16373581
caveolae pip2;increase;reperfusion 2 min;0;16373581
study;regulate;lh;2;16340166
bnst na input;suppress;receptor lh secretion;2;16340166
estrogen;enhance;suppression;0;16340166
alpha1-adrenergic receptor;mediate;norepinephrine;2;16225747
ar;mediate;norepinephrine;2;16225747
alpha1-adrenergic receptor;mediate;epinephrine;2;16225747
ar;mediate;epinephrine;2;16225747
acth response sensitisation;block;benoxathian;0;16219005
acth response sensitisation;block;benoxathian;0;16219005
response;inhibit;egf;2;16020479
fast;regulate;gnrhr level;2;24375763
diet;increase;insulin sensitivity;2;2437324311606777118183631186770512543260151410921516622630448822180312190846225202838429371791435020045141204135112053889620554934208711322119373521258337212823642141185921346062214020692171953422205519223029391090547215213227111934537248043535532378247133304351592456816000018160540991630637216702333168008461680193116914547172763531790922418317565182855531876568019120448191986471900922819414512195092791947070419956092198338902010371079842368001743756826474939651393336032781943281433328143422778500227922342271880922787141230520972323648523663741236637422388119023801581238138051123878315855324
beta1-adrenergic receptor;activate;glucose uptake;2;15665039
mab;inhibit;cd40 expression increase;2;15614043
inhibitor;inhibit;cd40 expression increase;2;15614043
rapamycin;increase;lifespan;0;24304444
rapa;increase;lifespan;0;24304444
urapidil tissue preperfusion;inhibit;glucose decrease;2;15090628
urapidil;enhance;concentration extracellular glucose level;2;15090628
flow;decrease;norepinephrine presence;2;15090628
orciprenaline;decrease;glucose concentration;2;15090628
sam;regulate;ecm degradation;2;25398607
lox expression;upregulate;belomycin;2;25348956
t. matsutake mycelium extract;decrease;activity;0;25319362
tropoelastin expression;increase;fibroblast;0;25319362
mmp-1 induction t. matsutake mycelium extract effect;mediate;fibroblast p38 inhibition;0;25319362
collagen increase;increase;session number;0;24641603
decrease elastin content increase;increase;session number;0;24641603
elastin content;decrease;age;0;2456157924637262
iium fibroblast treatment;up-regulate;67-kda elastin protein production;2;24525372
ear cartilage chondrocyte culture ltbp-2 addition;block;elastinogenesis;2;24148803
collagen mimetic peptide;mediate;protein self-assembly;0;25390880
lp;activate;mapk pi3k\/akt signaling pathway;2;25390332
fak ko wound;decrease;collagen density;2;25389925
igf-1;enhance;bone marrow stem cell differentiation;0;25388971
igf-1;activate;mtor signaling pathway;0;25388971
rapamycin mtor inhibitor;block;differentiation;0;25388971
ng\/ml igf-1;enhance;dpsc proliferation ability;0;25388971
addition;inhibit;marcksl1-induced apoptosis;2;24863880
loxl2 over-expression;inhibit;marcksl1-induced apoptosis;2;24863880
marcksl1;suppress;loxl2-induced oncogenesis;0;24863880
i collagen protein;decrease;matrix decrease collagen;0;25387264
cmc;decrease;collagen deposition;2;25386220
tgf 1 sirna vector;downregulate;tgf 1 expression;0;25385392
tgf 1 sirna vector;suppress;reaction;0;25385392
ldr;upregulate;collagen type i alpha 1 expression;2;25384363
ro;regulate;crystal formation growth;2;25383321
ro;regulate;crystallization modulator production retention;2;25383321
lkb1-deficient lung adc lysyl oxidase reduction;decrease;collagen disposition;2;2453112812577300129255201472956961318921881905192837084627428163675769897297314851049888415655419157699401616946416413471161872771624744416642001167150761673023716977322171865321728736317676035179344491759904818948947191118791940365619440335195615891966267719801978199311522012641020161759205591492066865820594926209563212103444121107086211244502112445121124456211024332110243421248838213166032143026921127502214719652223778122411819224643341067663411415930117516301253823822980975229607452362678324196716
lkb1-deficient lung adc lox reduction;decrease;collagen disposition;2;2453112812577300129255201472956961318921881905192837084627428163675769897297314851049888415655419157699401616946416413471161872771624744416642001167150761673023716977322171865321728736317676035179344491759904818948947191118791940365619440335195615891966267719801978199311522012641020161759205591492066865820594926209563212103444121107086211244502112445121124456211024332110243421248838213166032143026921127502214719652223778122411819224643341067663411415930117516301253823822980975229607452362678324196716
architecture bmsf scaffold;enhance;proliferation;0;25383171
iium fibroblast treatment;up-regulate;67-kda elastin protein production;2;24525372
vegf expression;upregulate;gel gel hcc cell;0;24472554
akt phosphorylation level expression;upregulate;gel gel hcc cell;0;24472554
signal;activate;pi3k\/akt pathway;2;24472554
signal;upregulate;vegf expression;2;24472554
ctgf;increase;oxidase;0;24469458
silencing;enhance;egfr;2;25381040
silencing;enhance;igf-1r phosphorylation;2;25381040
proanthocyanidin;mediate;collagen cross-linking;2;25379878
pac;mediate;collagen cross-linking;2;25379878
proanthocyanidin;enhance;dentin collagen base tissue property;2;25379878
pac;enhance;dentin collagen base tissue property;2;25379878
pac;decrease;collagen digestion;2;25379878
copper chelation therapy;increase;cancer cell stress;0;24210000
pai-1;inhibit;vegfr-2 binding;2;25378411
pai-1;inhibit;vegfr-2 binding;2;25378411
collagen;mediate;oxidase increase;0;24120383
igf-1ea col1a1\/3a1 mrna;increase;immobilisation;0;24081158
summary;regulate;collagen maturation;2;240062581201539015866165125356441458489514612392150905513201241248227478916798659519918276416023633161673281685497617085452172377931755096617194222182473401883496818927151186840911922498419458888205515132070859420605916216707572245305822160436152697091093799811277264117191911174119391827659557891991679210201372155764041554526215686623158661631586616412408869
lj-1888 pretreatment;inhibit;collagen i;2;24001475
lox increase expression;inhibit;osteosarcoma cell proliferation;2;23970168
lox increase expression;inhibit;osteosarcoma cell migration;2;23970168
brucine;suppress;hif-1-dependent luciferase activity;2;23933019
icariin;suppress;bone degradation;2;25374443195199241956161820131262204937322051913821401606212448602138063622128079232515122328030823746958239673272384556724504805247571441496905416329095173750961736330017277312178783251845125918682033189821601935884120116661
collagen fiber cross-link formation;regulate;lysine hydroxylase action;0;23902273
collagen fiber cross-link formation;regulate;oxidase action;0;23902273
ape;decrease;tgf 1 elevation;2;25373883
2.6 5.2;decrease;tgf 1 elevation;2;25373883
ape;decrease;collagen i elevation;2;25373883
2.6 5.2;decrease;collagen i elevation;2;25373883
ape;decrease;collagen iii expression elevation;2;25373883
2.6 5.2;decrease;collagen iii expression elevation;2;25373883
ape action mechanism;decrease;tgf 1 level;2;25373883
ape action mechanism;block;tgf \/ smad signaling pathway;2;25373883
response cox-2 activation;mediate;pik3\/akt pathway;2;25371970
28 day rat mc fruit extract administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
28 day rat 1.5 body weight administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
ctgf mrna;increase;group;0;23741440108692732219721611485970118466091261822112944550145538321537632142804723469602146021922243393299629679721104350301556179715949473159560331710983717497204178491721767321818375200184748151856062118535174187739831905000819265089193596641978714719949426200533512041161920472764206784742065095721219908212157562145121321455304218206052105935210986582
p190b overexpression;regulate;interaction;0;2371768917662267146100601970330119931152198264151985759220545614205919882116134120810549209804422161119321665151217609212182294521917992223519252281081020860838234999921187497815117886853734797001731002539810328216161694681652445116598650165721881646976917038622183584271844241218342983187835491892296818948007191536741808692312057913122377741453457719296884
paracrine;activate;tgf;2;2371768917662267146100601970330119931152198264151985759220545614205919882116134120810549209804422161119321665151217609212182294521917992223519252281081020860838234999921187497815117886853734797001731002539810328216161694681652445116598650165721881646976917038622183584271844241218342983187835491892296818948007191536741808692312057913122377741453457719296884
p4;increase;testosterone;2;23665105
bxpc3 tumor cell tgfbus addition;inhibit;growth;0;2536940210681566241361661170587111598108121869491261188010352148162349851644031116912190172758381806862918245446183621841806576218373849191179851959003619387070194742922043243520509890205062382128909321461859213986982170177622223527227851172264087822695319232849372333550723761027237921742381092211004666
bxpc3 tumor cell tgfbus addition;inhibit;migration;0;2536940210681566241361661170587111598108121869491261188010352148162349851644031116912190172758381806862918245446183621841806576218373849191179851959003619387070194742922043243520509890205062382128909321461859213986982170177622223527227851172264087822695319232849372333550723761027237921742381092211004666
procedure;increase;collagen synthesis;2;25367711
r;inhibit;vitro fibroblast type i tgf effect;2;23542580
r;inhibit;vitro fibroblast alpha smooth muscle actin expression tgf effect;2;23542580
r;inhibit;vitro fibroblast property tgf effect;2;23542580
atorvastatin;increase;bax reaction intensity;2;25366571
glycosylate lumican stimulation;increase;collagen type;2;23480731
glycosylate lumican stimulation;increase;collagen type;2;23480731
glycosylate lumican stimulation;increase;collagen type;2;23480731
1 mrna;increase;collagen type form level;2;23480731
phosphatase;enhance;pi3k\/akt signal pathway;2;25364523
tensin homolog;enhance;pi3k\/akt signal pathway;2;25364523
pten;enhance;pi3k\/akt signal pathway;2;25364523
activity;enhance;pi3k\/akt signal pathway;2;25364523
rgs5 deficiency;decrease;collagen content;2;25363362
collagen crosslink;enhance;tumor cell persistence;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;enhance;survival;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;increase;tumor cell proliferation;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;enhance;colonization;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;enhance;growth;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
gen;block;tak1\/mkk4\/jnk pathway;2;25362897
lox;activate;akt;2;231885041534278115136787246307616803558756718155857541634100716355214163665981695323816981251170794391729030817485314177072701807136318234994182454461807530218463380186508351858667819111879188140431948738119667273199311522002942120571069208183762112668721324931212394732128256421376230210575382183595216642001106479311074912012154058123602761274168212748309128908411000501
lox;activate;akt;2;231885041534278115136787246307616803558756718155857541634100716355214163665981695323816981251170794391729030817485314177072701807136318234994182454461807530218463380186508351858667819111879188140431948738119667273199311522002942120571069208183762112668721324931212394732128256421376230210575382183595216642001106479311074912012154058123602761274168212748309128908411000501
lox;activate;akt;2;231885041534278115136787246307616803558756718155857541634100716355214163665981695323816981251170794391729030817485314177072701807136318234994182454461807530218463380186508351858667819111879188140431948738119667273199311522002942120571069208183762112668721324931212394732128256421376230210575382183595216642001106479311074912012154058123602761274168212748309128908411000501
vegf;increase;lox activity;0;22966818
vegf;increase;expression;0;22966818
matrix metalloprotease;increase;glucose concentration increase;2;22966818
mmp;increase;glucose concentration increase;2;22966818
activity;increase;glucose concentration increase;2;22966818
conclusion;inhibit;pi3k\/akt pathway;2;25356754
pkd1 ectopic expression;up-regulate;cyclin d1 proliferation marker;2;227917101578214915675572157784651609804016096638162940321689922416912074175080281737031117707375179628091808980218559498193299941924359420442301203637542073291420940406206210682085741821357900115145711177794111741879119121331194358712223477124960571262241112824383136785751367858214673164150905931509806615448698864936215728188
type i collagen expression;increase;concentration manner;0;25352963
tgf expression;increase;emd 100 g\/ml;0;25352963
mo;enhance;collagen accumulation;2;2234811961480381706813836093271348714149790095243592820711106828021117367211557576116411441248263612589052128653401451287514632214146359351465473414677857746984867030521378618015569352155200181573629915998679160204641609345616367803163914331727639917510091176902951769193018086952182975691837230619079548190992411881829719255345191763501954623619592613196174081988756520170634203717342073431120622177209349712087675921674707213498232138967410070142167356423992061
addition;upregulate;ctgf expression;2;25351242
visfatin concentration hsc treatment;upregulate;ctgf expression;2;25351242
mo;enhance;collagen content;2;2234811961480381706813836093271348714149790095243592820711106828021117367211557576116411441248263612589052128653401451287514632214146359351465473414677857746984867030521378618015569352155200181573629915998679160204641609345616367803163914331727639917510091176902951769193018086952182975691837230619079548190992411881829719255345191763501954623619592613196174081988756520170634203717342073431120622177209349712087675921674707213498232138967410070142167356423992061
collagen secretion;decrease;a549 culture medium ls-102 synoviolin inhibitor addition;0;25351210
copper depletion;downregulate;vegf expression;2;2227622016278898161627121639750017065372182069651824618818322799184486751884283319028502191990361898995019111720197169662007304220562128109587981110478411254533115648851199766948581022071877446713686171961444688096378944530515526277156663661574122016357151
drug;block;lox loxl protein collagen cross-linking cd11b bmdc recruitment expression;2;2223174411152426116423591168988312615733126275231272686114507651150636851514495115488763441224787566168955077155925041584972716056258160966381634100716510593166420011723476417335808172446791700410617471532179143891818765318297062184384151853911219020076211613702118247821673063219113882186041019111879195498861980519219931152199463282002687420442288201519822081837620808300
hyperhomocysteinemia;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
hhcy;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
vegf;activate;anti-neovascularization mechanism;0;25349789
tetrathiomolybdate;inhibit;pulmonary microvascular cell proliferation;0;22162909106766581110478411134507111569581167383611858476118965711220873012676512127543781284414612952943401204421037114212590592172487021119733208338212516709750868389431899104943948696094907369581871103955841585201815931388157412201589723216456109167356741691458716924372174131271759634017652623182457761855662418774295190108711871250219808980198844661996537920117135205479272058501120508210
dn cell;activate;collagen transcription;2;25349198
dn mouse kidney;activate;collagen transcription;2;25349198
esa;inhibit;erk;2;25405982
stressed granulosa cell melatonin effect;inhibit;receptor antagonist luzindole;0;25405739
datum;inhibit;resveratrol;0;25405531
nctd;downregulate;mt1 mmp;2;25405519
cell apoptosis;increase;thymoquinone combination therapy;2;25405449
cell apoptosis;increase;doxorubicin combination therapy;2;25405449
protein mcl1-expressing cell apoptosis;regulate;mcl1 degradation;2;25404713
ga;enhance;bax expression;2;25403108
nsclc cell line technique igf2r inhibition;increase;proliferation migration invasion ability;0;25402559
igf2r silencing;enhance;nsclc cell line chemo-resistance;0;25402559
metformin;suppress;ampk activity;2;25402373
ezh2 gene;regulate;gene transcription;0;25400745
pi-103;inhibit;pi3k\/akt\/mtor activation;2;25400422
pkc isoenzyme;activate;messenger;0;25399568
pkc;regulate;proliferation;0;25399559
pkc;regulate;differentiation;0;25399559
pkc;regulate;apoptosis;0;25399559
pkc;regulate;response;0;25399559
msu crystal;increase;hek293 cell traf-6;0;25398539
msu crystal;increase;hek293 cell il-1 expression;0;25398539
msu crystal;inhibit;ascorbic acid;0;25398539
msu crystal ro accumulation ino cox-2 mrna expression;suppress;il-1 sirna transfection;0;25398539
therapeutics;block;cell proliferation;0;25398437
znf667;inhibit;rat proapoptotic gene bax gene promoter activity;2;25397408
znf667;mediate;bax mrna protein expression inhibition;2;25397408
tgf-beta1;down-regulate;gc expression;0;25395673
ionomycin;decrease;effect;0;25395331
pten;upregulate;pathway;0;25395086
ht1080 fibrosarcoma cell proliferation rate;suppress;apoptosis induction scutellarein treatment;0;25394920
treatment;inhibit;stat3 phosphorylation level increase;2;25394909
mirna inhibition;increase;ngf secretion;2;25394845
egfr signaling;block;construct rna vector;0;25394504
egfr signaling;block;lv-shrage;0;25394504
megfl;increase;expression level;0;25394497
megfl;increase;expression level;0;25394497
megfl;increase;p53 expression level;0;25394497
megfl induce;increase;cell protein expression;0;25394497
pten;upregulate;eb morphogenesis;0;25394489
pten;mediate;cavitation;0;25394489
hif-2;upregulate;pten;2;25394489
glucose presence;inhibit;cell proliferation;0;25394466
zol;suppress;topoisomerase ii activity;2;25393473
ask1 siah1 phosphorylation;activate;target acetyltransferase;2;25391652
modifier;regulate;protein degradation process;2;25391492
sumo;regulate;protein degradation process;2;25391492
datum;increase;24 hr induction;0;25388834
rmvec lox-1 protein expression;suppress;ampk re-enhanced;2;25388834
cm;up-regulate;bax level;2;25387796
therapy;block;interaction;0;25387682
p15ink4b overexpression;upregulate;bax expression;2;25387678
effect;mediate;bax cyclin d1 reduction;2;25387678
effect;mediate;bax cdk4 reduction;2;25387678
effect;mediate;bax regulation reduction;2;25387678
effect;mediate;bcl-2 cyclin d1 reduction;2;25387678
effect;mediate;bcl-2 cdk4 reduction;2;25387678
dna methylation;regulate;vegf-c expression;2;25387667
ap;regulate;pi3k\/akt pathway;2;253862261121228124916696124793671259176212767102154666472300383158118671665148216651473175627001834738319103993199600072133029321698274206202042172462222080862222927912266652022966413231041322372872324356372244549892479951511759175
phosphatase;regulate;stat3 activity;2;25386075
vegf restoration;upregulate;akt expression;2;25385479
tgf 1 sirna vector;downregulate;tgf 1 expression;0;25385392
tgf 1 sirna vector;suppress;reaction;0;25385392
process;activate;scarcity trigger response;2;25385287
tgf 1 treatment;increase;cell;0;25385280
melatonin;decrease;mammary cell proliferation viability induce apoptosis;0;25384569
sik1 mediate knockdown;increase;adenocarcinoma cell line migration;2;25384047240867171008253811208554111131181146385211701448118466091201088515721472161489431621929217114342171577921717070417185632174180101746876717470638173406241769408618297396183218491872553619098422192445101894617519622832196290711947070321111741211935252199596023349925234080592380586112105855119717601220042312488236128915541452593214976552152803641551123779729297769693778933193578329512670964946310660591
endotoxemia;increase;insulin secretion;2;2538378111266364170538321286902615220194152974388270128158643101628323717210129170907511742696017456850175194231830514118326786192400621977614019748889197208021971577220362554204241622120653321233852212823612135608421636801222761522255838122465073228205102257287722893028232504882303178923416061237472452362965924186868243471742481636712235117
p53 function;regulate;senescence;0;25382750
p53 function;regulate;proliferation;0;25382750
tnklpdc cell line ezh2 down-regulation;increase;apoptosis;0;25382618
tnklpdc cell line ezh2 down-regulation;decrease;tumor viability;0;25382618
fdp-sr protection;enhance;p450scc expression;2;25382543
jm118\/erlotinib;enhance;erk akt phosphorylation;2;25382189
gpx4 knockdown gpx4 inhibitor;enhance;lipid peroxidation;2;25381820
nutlin-3a;block;p53 interaction;2;25380055
nutlin-3a;block;mdm2 interaction;2;25380055
aspartate aminotransferase level;increase;male;0;25378801
alanine aminotransferase level;increase;male;0;25378801
aspartate aminotransferase level;increase;female;0;25378801
alanine aminotransferase level;increase;female;0;25378801
akt serine\/threonine kinase;increase;cell survival;0;25378391
macroh2a overexpression;inhibit;u2 os osteosarcoma cell progression;2;25378143
klotho expression;decrease;glucose tolerance;2;25377875
rab2a knockdown;inhibit;insulin secretion;2;25377857
klotho protein treatment;increase;foxo1 level;2;25377663
klotho protein treatment;decrease;foxo1 level;2;25377663
addition;suppress;foxo1 phosphorylation;2;25377663
klotho protein administration;suppress;foxo1 phosphorylation;2;25377663
addition;suppress;akt phosphorylation;2;25377663
klotho protein administration;suppress;akt phosphorylation;2;25377663
progesterone;suppress;signaling;0;25377472
tgf expression;decrease;dhm treatment;0;25376731
reduce cdk1 expression pluripotent stem cell;activate;chk2 expression;0;25375373
cd4 + + t cell percentage;decrease;aecopd scopd patient;0;25375131145829231254773315215480637413674918984309528784270103361731043075015536434157104681608184516113466162423111624653916443644175075451761497018285654183944321835588418769672186848441923422519494220197705212040266921367451212708292182300621821800218760322185516622823388226593912314177123749814245293902441830814510725107605451124356814654162
cd4 + + t cell percentage;decrease;aecopd patient;0;25375131145829231254773315215480637413674918984309528784270103361731043075015536434157104681608184516113466162423111624653916443644175075451761497018285654183944321835588418769672186848441923422519494220197705212040266921367451212708292182300621821800218760322185516622823388226593912314177123749814245293902441830814510725107605451124356814654162
rapamycin mtor inhibitor autophagy inducer;enhance;apoptosis;0;25375091
rapamycin;inhibit;vitro gist cell growth;0;25375091
bax expression;decrease;cord segment horn cell;0;25374594
mir 338-3p;downregulate;carcinoma tumor;2;25374067
lqc treatment;downregulate;hgf\/c meet signal transduction pathway;2;25373931
v myc oncogene homolog;regulate;cancer type cell proliferation;0;25373306
myc;regulate;cancer type cell proliferation;0;25373306
v myc oncogene homolog;regulate;cancer type differentiation;0;25373306
myc;regulate;cancer type differentiation;0;25373306
v myc oncogene homolog;regulate;cancer type apoptosis;0;25373306
myc;regulate;cancer type apoptosis;0;25373306
bmi1 knockdown;block;tumor growth;0;25372945
bmi1 knockdown;block;tumor growth;0;25372945
clathrin;transactivate;tumor suppressor p53;2;25372751
contrast;decrease;0.69 0.03 fold;0;25372635
insulin receptor substrate 1;mediate;pi3k\/akt signaling;2;25372512
irs1;mediate;pi3k\/akt signaling;2;25372512
osteoblast irs1 overexpression;activate;pi3k\/akt pathway;2;25372512
osteoblast irs1 overexpression;inhibit;nf bp65 expression;0;25372512
osteoblast irs1 overexpression;inhibit;bax expression;2;25372512
mer down-regulation;mediate;receptor internalization degradation;2;25372020
mdm2 expression level;decrease;tnf induction;0;25371717
dr3 silencing;inhibit;vitro carcinoma cell proliferation;2;25370568
dr3 silencing;inhibit;vitro carcinoma cell invasion;2;25370568
cisplatin;increase;egfr phosphorylation expression;2;25370413
paclitaxel;increase;egfr phosphorylation expression;2;25370413
paclitaxel;increase;egfr phosphorylation expression;2;25370413
pokemon;suppress;p14;2;25367850
vdr activation;inhibit;oxidative stress;2;25365634
stat3;activate;transform npc cell line;0;25365510153071422009820926917681183180464411799173510652427113953871243585612450731182020241827052018719201188295761881243919219043191854851927626119509158195468869072974909037995936641576107816024602161030531621056716314309165307031655727916762633172003441707234417327404195971531949367819641183198438432043841320363096208138332056366119435867205089452161179622066022219178572234742822374676223418102193072722154363225358632231894122402588224671012286837222834702226899222305203623099007234720692394061521444672124383131280959814532122
noxa upregulation;increase;cell mek\/erk signaling;2;25365078
action;mediate;estrogen receptor;2;25364741
phosphatase;enhance;pi3k\/akt signal pathway;2;25364523
tensin homolog;enhance;pi3k\/akt signal pathway;2;25364523
pten;enhance;pi3k\/akt signal pathway;2;25364523
activity;enhance;pi3k\/akt signal pathway;2;25364523
combination treatment;suppress;akt phosphorylation;2;25364470
level;increase;tumor protein p53;2;25364433
level;increase;p53;2;25364433
igf2;mediate;cell growth;0;25364428
igf2;mediate;apoptosis;0;25364428
gf109203x;suppress;osteoclastogenesis;0;25363829
gf109203x;suppress;activity;0;25363829
gf109203x;inhibit;calcium oscillation;0;25363829
gf109203x;block;function;0;25363829
cell death;block;erk1\/2 inhibitor;2;25363631
rgs5 deficiency;decrease;collagen content;2;25363362
phytoestrogen;inhibit;proliferation;0;25363142
akt protein level;decrease;hsf cell;0;25363142
akt protein level;decrease;hsf cell;0;25363142
dna damage response dbc1 sirt1 inhibition;activate;atm;0;25361978
ddr dbc1 sirt1 inhibition;activate;atm;0;25361978
event;increase;sirt1 inhibition;2;25361978
breast cancer;decrease;pten expression;2;25361177
bbc;decrease;pten expression;2;25361177
treatment;inhibit;xenograft pten null hcc-70 bbc cell;2;25361177
hnr expression;inhibit;female rat cell estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
tumor cell hnr expression;regulate;estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
cdkn3 overexpression;inhibit;cdk2-dependent xiap expression;2;2536062210669749245731791096189710979976109872701123489011463386124296441274507514737178150325711379313824275081278737698009100851151583385916322690169516851721069218042805183729191923814819150984196260052044026620574455209525112131927321965652219900312215654922318733227874352294866221396835237751902374963923954782238911892439150110727459
pkc silencing;increase;gcdc induce jnk;0;25359536
pkc silencing;decrease;gcdc induce akt phosphorylation;2;25359536
pkc silencing;increase;bim expression;0;25359536
trp53 deficiency;increase;ssc survival;0;2535879412574499124792241297250112851404149917511517300641938121005661149333159475476862577972053898066594968899707592102031831020052210330102156203581703564216377624156019131724220917376750182858031837143818522850189869801911800619056683194177772017704820711434208183882112311921450905224705102242196822779927229952142341730023746981109499341110590411511362118840271202103412700182
mir-199a;regulate;cd44 expression;2;25400809
mir-199a;regulate;cd44 expression;2;25400809
mir-199a;regulate;cd44 expression;2;25400809
uvb exposure;suppress;rassf1a expression;2;25392149
e1 e2 adiponectin association;mediate;bmus;0;25405497
ft adiponectin association;mediate;bmus;0;25405497
obesity;decrease;adiponectin secretion;2;25400997
obesity;decrease;adiponectin secretion;2;25400997
addition;increase;insulin secretion;2;25388925
two ghrelin administration regimen;suppress;inflammation;0;25377269
candidate endocrine analysis;upregulate;morph;0;25369871
tgf;suppress;melanomagenesis;0;25363621
mouse protein c activate agent protac administration;enhance;octanoyl ghrelin production;2;25349251
acth amount;decrease;uvb irradiation;0;25345490
msh amount;decrease;uvb irradiation;0;25345490
ghrelin;inhibit;activity;0;25337654
mixed glucose\/protein beverage intake;decrease;boy level;0;25308907
bmal1;increase;melanin content protein expression;0;25310406
per1 silencing;increase;melanin content protein expression;0;25310406
bmal1;increase;skin activity;0;25310406
per1 silencing;increase;skin activity;0;25310406
melanocyte bmal1;increase;activity;0;25310406
melanocyte per1 silencing;increase;activity;0;25310406
melanocyte bmal1;increase;tyrp1\/2 expression;0;25310406
melanocyte per1 silencing;increase;tyrp1\/2 expression;0;25310406
ghr 0.3 nmol \/ l administration;increase;lhcgr gene expression;2;25286107
hexarelin growth hormone-releasing peptide;activate;growth hormone secretagogue receptor;0;25278975
hexarelin growth hormone-releasing peptide;activate;growth hormone secretagogue receptor;0;25278975
hexarelin growth hormone-releasing peptide;activate;ghsr;0;25278975
hexarelin growth hormone-releasing peptide;activate;ghsr;0;25278975
receptor expression;activate;egf receptor;2;25385589
receptor expression;activate;egfr;2;25385589
ghrelin administration;decrease;heart rate;0;25265271
ghrelin administration;decrease;blood pressure;0;25265271
testosterone;decrease;stressed male;0;25236886
castration;increase;stat3 activation;2;19628067164276501600709616690882168205871723496317114246175952171767557511241353109742281882476711524388119944011221917912571365127545071519202077579738640972943563210072236153748311536739316439666
dht replacement;decrease;stat3;2;19628067164276501600709616690882168205871723496317114246175952171767557511241353109742281882476711524388119944011221917912571365127545071519202077579738640972943563210072236153748311536739316439666
ati;decrease;stat3;2;19628067164276501600709616690882168205871723496317114246175952171767557511241353109742281882476711524388119944011221917912571365127545071519202077579738640972943563210072236153748311536739316439666
testosterone rhythm;enhance;monkey;0;18367678
testosterone decrease;mediate;enzyme number gene expression change;0;16102138
testosterone decrease;mediate;transport protein number gene expression change;0;16102138
chi3l1 mrna;increase;colon carcinogenesis progression;2;254004571850274318490894194392291959695319908331197677682052486621763261219386822215733122475725227017572273265122241684231693092392558912124825126734921008665510443931160815111647259517211147177032111789303217725598
serum testosterone;increase;administration;0;10591424
serum testosterone;increase;1.98 ng\/ml;0;10591424
mph;inhibit;dat;2;25414770
disorder substance alcohol abuse comorbid;increase;rapid cycling risk;2;25413561
hesperidin;decrease;bax protein expression;2;2536905315023560128888801536381515479036760819368108689809980954310048147155396391594131116343469167008251689100917084010173715271735631017654445180573391462302614691289178978171808615318398339184371501862078419118026200268691977587721320264238319691070551110963718111605391208706412088279122209631257165415113710
akt inhibition;increase;cholesterol efflux;0;25415591
akt;suppress;cholesterol efflux;0;25415591
target akt;regulate;apoa-i cholesterol efflux;0;25415591
akt;regulate;apoa-i cholesterol efflux;0;25415591
rapamycin;increase;mouse longevity;0;25414638
mtor kinase inhibitor;increase;mouse longevity;0;25414638
rapamycin;increase;brain lysate activity;0;25414638
streptozotocin;decrease;glp-1 concentration;2;25065315
streptozotocin;decrease;insulin concentration;2;25065315
reference drug sitagliptin;increase;incretin insulin contents;2;25065315
opc differentiation rheb1 effect;mediate;phenocopy olig1-cre rheb1 deletion olig1-cre deletion mtor;2;25411504
control group;increase;glucose level;2;24771372
glucose level;decrease;day 16;0;24771372
datum;inhibit;resveratrol;0;25405531
metformin;suppress;ampk activity;2;25402373
insulin sensitivity vascular function hf symptom;enhance;diastolic function;0;25394648
insulin sensitivity vascular function hf symptom;enhance;vascular function;0;25394648
insulin sensitivity vascular function hf symptom;enhance;energy metabolism;0;25394648
hce75;increase;system serotonin dopamine level;2;25179173
400 mg\/kg;increase;system serotonin dopamine level;2;25179173
p.o.;increase;system serotonin dopamine level;2;25179173
complex;activate;rheb;2;25402640
sirt1 level;decrease;test scrapie-infected model;2;25391763
ampk;regulate;nf b activation;0;25401040
degradation protection;increase;mdm4 protein level;0;25394965
pi3k\/akt pathway regulator;inhibit;hesperidin;0;25047426
tumorigenesis intervention effect;mediate;sirt1 activity modulation;2;2538003422986747226613832298237723298290232551282310410123169992234261802298653524278473242977002332982610693811108119201084156311606380116725221167252312611451149802221515219015126506152054771528673813122208405212967138815744310156925601571626815684413157497051626933516626303169988101708619117638871176200571780610218046409179588961841467918523577185994491883503318851829186385381913030519364925194609981950310019995796206209562110263321224077210568972109872521569839219208992200615622290875222664662247013222560220218132712258583022554968228832302305095922730114
p27 expression;suppress;tg mouse myocardium;0;25394488
pleiotropic action mechanism;block;carcinogenesis;2;25365584
igf-1;enhance;bone marrow stem cell differentiation;0;25388971
igf-1;activate;mtor signaling pathway;0;25388971
rapamycin mtor inhibitor;block;differentiation;0;25388971
ng\/ml igf-1;enhance;dpsc proliferation ability;0;25388971
ampk;block;chemical inhibitor compound c;0;25382002
metformin;decrease;mouse blood glucose;2;25382002
glibenclamide;decrease;mouse blood glucose;2;25382002
insulin;upregulate;hl-7702 cell tfr1 protein mrna level;0;25385842
piceatannol;upregulate;sirt1 mrna expression level;2;25360511
resveratrol;upregulate;sirt1 mrna expression level;2;25360511
piceatannol;upregulate;sirt1 protein expression level;2;25360511
resveratrol;upregulate;sirt1 protein expression level;2;25360511
mtor deletion;suppress;class switching center response;0;25385646
mtor deletion;suppress;hypermutation center response;0;25385646
rsv;upregulate;liver sirt1 level;2;2535200811874812238721301512088315353412846443480079869032113104914081617972716227462163099611708619117112576172727861790855118250205182502141945517919641587205263832097472921241768216320752196533021950773223090332256473122209670218132712262716922587629229170162208130823185430231901272329209823462891236146932344849012939617
grim 19 overexpression;suppress;stat3 signaling pathway;2;25351437
resveratrol stat3 phosphorylation suppression;decrease;sirna treatment;0;25351437
28 day rat mc fruit extract administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
28 day rat 1.5 body weight administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
s6k1 activation;decrease;pten deletion effect;2;25382660
s6k1 inhibition;decrease;pten deletion effect;2;25382660
s6k1 activation;regulate;growth;0;25382660
s6k1 inhibition;regulate;growth;0;25382660
gene il-22-induced stat3 phosphorylation;inhibit;metformin;0;25370454
d1 il-22-induced stat3 phosphorylation;inhibit;metformin;0;25370454
cell differentiation metformin effect;mediate;stat3;2;25370454
cell differentiation metformin effect;mediate;stat4 phosphorylation;2;25370454
glucagon auc0-180 min;increase;dapa+meet;0;25370334
selumetinib;inhibit;erk1\/2 phosphorylation;2;253790211546746824756797171219141733230417360704176997181839096819071109193725561940144919588372196373121978389820484037200479532058766720704563209238572122022321447798214646132170828421725613117303231250976314581487154708957041539910225599898331039532715543157220482372256900022287190232028892326135622972589234442152390375516273091
p450 expression;regulate;liver pxr activation;0;25341566
cyp450 expression;regulate;liver pxr activation;0;25341566
nanocrystal;increase;saturation solubility;0;24813782
nanocrystal;increase;skin penetration;0;24813782
knockdown contrast rictor overexpression;suppress;fc ri-mediated degranulation;0;25378594
sesn3;activate;mtorc2;2;25377878
bafilomycin a1 autophagy inhibition;inhibit;protein synthesis;0;25376834
acid scarcity treatment autophagy inhibition;inhibit;protein synthesis;0;25376834
bafilomycin a1 autophagy inhibition;inhibit;acid supplementation;0;25376834
acid scarcity treatment autophagy inhibition;inhibit;acid supplementation;0;25376834
rapamycin mtor inhibitor autophagy inducer;enhance;apoptosis;0;25375091
rapamycin;inhibit;vitro gist cell growth;0;25375091
nso;increase;testosterone semen characteristic gsh;2;25425536
insomnia therapy;regulate;cycle;0;25423562
amylin;increase;leptin signaling;0;25409701
amylin;increase;stat3 phosphorylation;0;25409701
amylin;increase;phosphorylation;0;25409701
vasopressin\/oxytocin family hormone;regulate;behavior;0;25425529
interfere rna pkc pam prrsv infection activate pkc;suppress;prrsv replication;0;25155198
interfere rna pkc knockdown prrsv infection activate pkc;suppress;prrsv replication;0;25155198
sirna pkc pam prrsv infection activate pkc;suppress;prrsv replication;0;25155198
sirna pkc knockdown prrsv infection activate pkc;suppress;prrsv replication;0;25155198
cos-1 cell vp22-myc trafficking;enhance;msc modification;0;24955582900816323360350110163241128366911343414115352331177288212517467125791061267920412910262128791521455080414575695128813059269047948865095923919701245776141389582149916985100744871010281410198183159832411618391616198853165221661667430016624621170465841723530917518565175566661747858417644515177218741835681518752428191961391987540319724264203504882045861521249477152467261524298110567312
cos-1 cell vp22-egfp trafficking;enhance;msc modification;0;24955582900816323360350110163241128366911343414115352331177288212517467125791061267920412910262128791521455080414575695128813059269047948865095923919701245776141389582149916985100744871010281410198183159832411618391616198853165221661667430016624621170465841723530917518565175566661747858417644515177218741835681518752428191961391987540319724264203504882045861521249477152467261524298110567312
cos-1 cell egfp-vp22 trafficking;enhance;msc modification;0;24955582900816323360350110163241128366911343414115352331177288212517467125791061267920412910262128791521455080414575695128813059269047948865095923919701245776141389582149916985100744871010281410198183159832411618391616198853165221661667430016624621170465841723530917518565175566661747858417644515177218741835681518752428191961391987540319724264203504882045861521249477152467261524298110567312
msc vp22-myc trafficking;enhance;msc modification;0;24955582900816323360350110163241128366911343414115352331177288212517467125791061267920412910262128791521455080414575695128813059269047948865095923919701245776141389582149916985100744871010281410198183159832411618391616198853165221661667430016624621170465841723530917518565175566661747858417644515177218741835681518752428191961391987540319724264203504882045861521249477152467261524298110567312
msc vp22-egfp trafficking;enhance;msc modification;0;24955582900816323360350110163241128366911343414115352331177288212517467125791061267920412910262128791521455080414575695128813059269047948865095923919701245776141389582149916985100744871010281410198183159832411618391616198853165221661667430016624621170465841723530917518565175566661747858417644515177218741835681518752428191961391987540319724264203504882045861521249477152467261524298110567312
msc egfp-vp22 trafficking;enhance;msc modification;0;24955582900816323360350110163241128366911343414115352331177288212517467125791061267920412910262128791521455080414575695128813059269047948865095923919701245776141389582149916985100744871010281410198183159832411618391616198853165221661667430016624621170465841723530917518565175566661747858417644515177218741835681518752428191961391987540319724264203504882045861521249477152467261524298110567312
datum;inhibit;hcv cation conductance;0;24726442
method spectrometry configuration advance;increase;interaction dataset quantity;2;24671686
bioinformatic tool advance;increase;interaction dataset quantity;2;24671686
method spectrometry configuration advance;increase;interaction dataset quality;2;24671686
bioinformatic tool advance;increase;interaction dataset quality;2;24671686
ns5a expression;enhance;glucose consumption;2;2439032119297321191016341985720419793818200625262013910321056986211469932148998821779165238247942259358622127214237758942330154223462180236299242383623412072493276635391578296495091341664313575683156993491610318716484368168920821696375717173481177847841809814618187620188206841885415418985028189769751915619519460998
lha;regulate;body fluid;0;25431553
lha;regulate;energy homeostasis;0;25431553
mph;inhibit;dat;2;25414770
200 g\/kg dose administration;increase;testosterone 1;2;25430649
hnr expression;inhibit;female rat cell estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
tumor cell hnr expression;regulate;estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
vasopressin\/oxytocin family hormone;regulate;behavior;0;25425529
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
200 g\/kg dose administration;increase;testosterone 1;2;25430649
hnr expression;inhibit;female rat cell estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
tumor cell hnr expression;regulate;estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
mph;inhibit;dat;2;25414770
200 g\/kg dose administration;increase;testosterone 1;2;25430649
hnr expression;inhibit;female rat cell estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
tumor cell hnr expression;regulate;estrogen;2;25360890110954882485927811371646121540111219357712732850145618951467468515106598151283891515353015235106841761815475661155283001565525515661735156617371575913416005025160998641661923318261827191583231938676119623253199522751980008319997871206164922045659620562421210988602054250120980730214649942229865022328926225223112284445323239898232203342368688823861391239853502434193811327724
mph;inhibit;dat;2;25414770
vasopressin\/oxytocin family hormone;regulate;behavior;0;25425529
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
nr0b2;mediate;testosterone synthesis repression;2;25426871
serotonin depletion;block;cytisine effect;0;25288485
hippocampus raphe 5-ht1a receptor knockdown;decrease;cytisine effect;0;25288485
mph;inhibit;dat;2;25414770
contrast;increase;stimulation site distance;0;14672999
insulin secretion hyposmotic stimulation;inhibit;noradrenaline;2;17065814
irap\ per p-lap distribution;regulate;hormone;0;12700100
irap\ per p-lap distribution;regulate;exercise;0;12700100
vasopressin concentration;increase;one;0;1199090511990939
vasopressin;mediate;v1 receptor activation vasoconstriction;0;157740809054839921818292679389386112942599995188669832689100678571022178510403611104477871051253310528604142015461056731110654495107289621111613411373409114293291143652211511958115555381166942511873030118936001195554211990905125945906336915682400561977153999236299729330005122950136326170229029882916660290716632534422764128254840827915892529763230295321979122169286224243918520131884613155818315721851303622161797113872931329579838743684985907686696837029283965248404107821414281314748160864806738575289967813742127326001279441612856123146055371463355514665508147075791476758414673520150909744299187434238048269271671491816307440213734677349918615633570284667345850713735871490506849407785991477156467498282864891386737529054835
shock patient 0.01 -0.04 u\ per min vasopressin infusion;increase;plasma vasopressin concentration;0;157740809054839921818292679389386112942599995188669832689100678571022178510403611104477871051253310528604142015461056731110654495107289621111613411373409114293291143652211511958115555381166942511873030118936001195554211990905125945906336915682400561977153999236299729330005122950136326170229029882916660290716632534422764128254840827915892529763230295321979122169286224243918520131884613155818315721851303622161797113872931329579838743684985907686696837029283965248404107821414281314748160864806738575289967813742127326001279441612856123146055371463355514665508147075791476758414673520150909744299187434238048269271671491816307440213734677349918615633570284667345850713735871490506849407785991477156467498282864891386737529054835
interaction;mediate;gfap;2;199365681568093915745952186558801882396119037321182821601057502011012836115497211219522412372001124924271260949912859353128996821455287414617676147242601513521915134863151537534577217123694870397667199961733880763653286462460638494624127002422592158936411578943040847951592262215961240160149241599570116134141162164211650392016322347165545011681614416832906166449071684276317127302170316681731428617241122176631381767895717628000176930271768401417714952173932981807769418082334183675041829340418439402184627961862606518655876188033081921188119267953379509335675803109879281977024438642451734340445930445183044521318019325651532202017161744384693137891864770847477762337615871884710288096728839353895163689773829354336953012897951471535618715610159
interaction;mediate;gfap;2;199365681568093915745952186558801882396119037321182821601057502011012836115497211219522412372001124924271260949912859353128996821455287414617676147242601513521915134863151537534577217123694870397667199961733880763653286462460638494624127002422592158936411578943040847951592262215961240160149241599570116134141162164211650392016322347165545011681614416832906166449071684276317127302170316681731428617241122176631381767895717628000176930271768401417714952173932981807769418082334183675041829340418439402184627961862606518655876188033081921188119267953379509335675803109879281977024438642451734340445930445183044521318019325651532202017161744384693137891864770847477762337615871884710288096728839353895163689773829354336953012897951471535618715610159
cell contrast;increase;cell firing rate;0;15214863
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
mch-r2;mediate;mch effect;0;17324419
avp;mediate;acth response;2;11488255
ot;mediate;acth response;2;11488255
vitro;inhibit;acth secretion;2;11488255
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
transport animal plasma acth;increase;1h;0;17029676
cortisol concentration;increase;transportation response;0;17029676
ntc animal crf injection;increase;plasma acth;2;17029676
ntc animal avp injection;increase;plasma acth;2;17029676
decrease ap;regulate;acth secretion duration;2;17029676
crf;regulate;acth secretion duration;2;17029676
avp;regulate;acth secretion duration;2;17029676
contrast calcium level;increase;stimulation frequency;0;10995820
melatonin;suppress;rat system vp release;0;20814074
pituitary gland;increase;insight;0;15906316
arc neuron;activate;foot shock stress;0;19501488
picrotoxin;block;vasopressin oxytocin release increase;2;14552874
-;block;vasopressin oxytocin release increase;2;14552874
channel;block;vasopressin oxytocin release increase;2;14552874
blocker;block;vasopressin oxytocin release increase;2;14552874
otp null hypothalamus;secrete;neuropeptide somatostatin arginine vasopressin oxytocin hormone;2;11071765
expression level;regulate;gnrh;2;22640608
hyperosmolality;inhibit;vasopressin neurone expression;2;15089976
pvn avp neuron;activate;depression;0;17524488
datum;increase;hb size;0;1589457627641358968267753792674855718612404863949190406969362271957515896612039746481984147998146169926800102297331047144815709954109937491064468412003834120427761200656712235032122350501280502412826074127944261281674614595407147454611459293814990349115446734786948765210877982088979928156623
datum;increase;hb size;0;1589457627641358968267753792674855718612404863949190406969362271957515896612039746481984147998146169926800102297331047144815709954109937491064468412003834120427761200656712235032122350501280502412826074127944261281674614595407147454611459293814990349115446734786948765210877982088979928156623
tgfbeta;secrete;neurohypophysis;0;15214860
tgfbeta;regulate;pituitary cell proliferation;0;15214860
tgfbeta;regulate;pituitary cell secretion;0;15214860
aii;mediate;pvn excitability;2;10795918
vasopressin two nonapeptide;secrete;neurohypophysis;0;10795914
gnrh two form;regulate;axis;0;10753567
gnrh-i two form;regulate;axis;0;10753567
pituitary gland;inhibit;gaba release;0;12488823
adiponectin;activate;ampk;0;18725075
food intake;regulate;ampk signaling pathway;2;18725075
metabolism;regulate;ampk signaling pathway;2;18725075
arc neuron number;increase;rat;0;17383023
npy administration;increase;food intake;0;21554973
npy administration;increase;food intake;0;21554973
transcription coactivator cited1;regulate;estrogen;2;17047318
transcription coactivator cited1;regulate;tgf-beta;2;17047318
cell contrast;increase;cell firing rate;0;15214863
monkey;increase;lh concentration;2;22949219
vasopressin addition;decrease;plasma 5-fu auc;0;16047145
origin;inhibit;acth secretagogue release;2;16395302
arginine-vasopressin;secrete;blood;0;12860046
fshr igf-1 expression;increase;group y1 y2;0;22500393
fshr igf-1 expression;increase;y3;0;22500393
vasopressin infusion;decrease;requirement;0;21161222
lh pulse frequency;decrease;infusion;0;18389014
lh pulse amplitude;decrease;infusion;0;18389014
contrast extracellular atp;inhibit;type ii k;0;10795908
contrast extracellular atp;inhibit;manner;0;10795908
contrast extracellular atp;inhibit;current;0;10795908
contrast;inhibit;n-type ca2 + channel;0;10795908
contrast;decrease;release;0;10795908
administration;increase;pomc expression;2;18359080
plasma vasopressin level;increase;period;0;17258819
result;increase;vasopressin half-life;2;17258819
cbd;decrease;increase sedation;2;14583744
pituitary gland;inhibit;gaba release;0;12488823
glucocorticoid;secrete;response;0;15994343
glucocorticoid;suppress;oxytocin activation;0;15994343
glucocorticoid;suppress;secretion activation;0;15994343
gnrh ii;regulate;production;0;12606432
gnrh ii analog;regulate;production;0;12606432
gnrh antagonist treatment;decrease;plasma lh;0;10864807
nal-glu;decrease;plasma lh;2;10864807
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
glucocorticoid action;increase;food salience;0;15240363
glucocorticoid action;increase;food ingestion;0;15240363
metformin insulin-sensitizing agent;decrease;appetite;0;2295006177373221709559396939341145759411602624120869351214515314742438150583051519508715375032162197201650523517717055182502731838276619819947195334811102456711735093118558501502872515680471158645309661644
dopamine;activate;production;0;15909246
plasma progesterone concentration;increase;week;0;20035106
vasopressin administration;suppress;latter activity;0;12866715
expression;decrease;lh surge;2;12700202
tnf-alpha;increase;dopamine dopac concentration;2;12207161
tnf-alpha;increase;axis turnover;0;12207161
activity increase;mediate;tnf-alpha effect;2;12207161
tgfbeta;secrete;neurohypophysis;0;15214860
tgfbeta;regulate;pituitary cell proliferation;0;15214860
tgfbeta;regulate;pituitary cell secretion;0;15214860
change;increase;insulin secretion;2;11224661
change;increase;growth hormone secretion;2;11224661
change;increase;cortisol secretion;2;11224661
change;increase;epinephrine secretion;2;11224661
change;increase;norepinephrine secretion;2;11224661
ang ii;regulate;thirst;2;15240355
pvn at (1)- receptor;regulate;hormone;0;15240355
pvn at (1)- receptor;regulate;crh;0;15240355
pvn at (1)- receptor;regulate;formation;0;15240355
pvn at (1)- receptor;regulate;release;0;15240355
acth;decrease;tnf release;0;10890565
stress response mediator glucocorticoid;inhibit;hormone receptor expression;0;22734562
stress response mediator glucocorticoid;inhibit;biosynthesis;0;22734562
pituitary gnrh-r differential distribution;regulate;endocrine cell;0;12153468
pvn;inhibit;tonic gabaergic input baroreflex;0;213682692900661613258620818137685780894589795939661044454615579055158541521568165616105820170718181730368218158342192547331962811119778682201643312050490721149828109035661129919911458692124243021249277412492775128325271451401812900439128812001459764643364303418014
urine cortisol;suppress;dose suppression test 95 %;0;2316643210720040181742871291567912930931145023621467118718322123034617955456786218487840669005978906150897687009793762103576961571765910857554
vasopressin v1a receptor mrna;increase;labor onset;0;11843375
pituitary gland;inhibit;gaba release;0;12488823
vegf administration;increase;follicle number;0;15271473
testosterone concentration;increase;period;0;11857464
testosterone concentration;decrease;mating period;0;11857464
stress hormone crf;inhibit;plasma testosterone level increase;2;18047555
catecholamine;inhibit;plasma testosterone level increase;2;18047555
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
glucocorticoid action;increase;food salience;0;15240363
glucocorticoid action;increase;food ingestion;0;15240363
food intake;inhibit;rat ghrelin treatment;2;16943587
ghrelin;mediate;gh secretagogue;0;12809167
ghrelin;mediate;gh;0;12809167
ghrelin;mediate;receptor;0;12809167
ghrelin;mediate;ghs-r;0;12809167
acid peptide;mediate;ghs-r;2;12809167
ghrelin;mediate;level type 1a;0;12809167
messenger molecule crosstalk;mediate;gnrh action;2;11358118
lh fsh binding;decrease;male;0;12324665
bp2;suppress;lh cholesterol ldl hdl;2;15951094
lh receptor binding;increase;forko mouse unit weight;0;11566744
expression level;regulate;gnrh;2;22640608
gh;inhibit;igfbp-5 expression;2;10959408
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
dose contrast;block;response;0;20720166
oligodeoxynucleotide endogenous per1;inhibit;frequency increase;0;17978049
progesterone;increase;t3 level;0;11428714
progesterone;decrease;t4 level;0;11428714
stage;decrease;pampk;2;24636512
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;cell proliferation;0;24860149
pdgfr vegfr kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
pdgfr sti571 kinase inhibitor azd2171 administration;decrease;opc proliferation;0;24860149
datum;regulate;apoptosis;0;171392521062689393364641082906611103792985922798745649883901991679210064597103639691045458510455112104901011052140415673569156893761579356515856027162314221625806316397499162936401645933016469767111758561140448111445538114814891151153311560952116064701204973812089360121249451220509512456808125546391275450512754506127545071281059312773095145726691458517014634621146394671499968215032587150790751536380715361843152922066488314246321284947848515078856582989068708961260909641010777583
testosterone concentration;increase;growth phase;0;18638138
cortisol plasma level;increase;surgery;0;19615860
vasopressin plasma level;increase;surgery;0;19615860
norepinephrine plasma level;increase;surgery;0;19615860
dopamine plasma level;increase;surgery;0;19615860
progesterone concentration;increase;pregnancy;0;12968945
progesterone concentration;increase;lactation;0;12968945
insulin plasma concentration;increase;mouse;0;20298457
recombination;mediate;posterior pituitary gland;2;23209739106866071106533811069887110878301110505511105057113010011198085015223342631940014959759177348168504731806467620147377202372812038673220890044
t3\ per rt3-ratio;increase;insulin subject;2;21104580
go serum level;suppress;plasma testosterone concentration;2;22380019
contrast;increase;corticosterone injection level;0;17064351
vasopressin concentration;increase;one;0;1199090511990939
pgfm concentration;increase;administration 4 h;0;11787156
stress regulation;mediate;pvn neurocircuitry mechanism;2;15717303
insulin;increase;cow proportion;0;11882019
acth cell treatment;increase;star cyp11a1 mrna expression;0;18609294
ewe acth secretion rate;increase;ewe comparison 1.5 factor;0;10698174
lhrh analog type;block;gonadotropin secretion;0;17237842
nkba-13;increase;goldfish hypothalamic salmon gnrh pituitary fsh lh mrna level;2;25448255
gonadectomy;increase;acth response;2;16879166
i;increase;acth response;2;16879166
hormone;suppress;testosterone level;2;10819455
relaxin-3 administration;increase;plasma acth level;2;24578294
therapy aim;decrease;level;0;16119107
cd8;decrease;treatment group;0;18822906
estrogen;regulate;nongenomic pathway aggression;0;24518867
erbeta;regulate;gnrh secretion;2;20308571146441301960259114993442147621701518723138652043112183245207225016672108012824329186501959048584917123197240539861029158936491579072715882902161998981629364116477031171104371747080517280790176153921745657517595316108103001107224111289127112891291198631612737678128737441289072099273301037502715591020157204731826832919407503194872811914889519491296194817991901300814657709
ecfp fluorescence;increase;pvn;2;20026620150578031458365115057822399865140938892434861245099932037403233346216832075259437545100868347010066257153750271696529617355318180883591854997418601686191999541915043719207829105837281053142719258662107959091121960811427695118615301209791112535153125889011296003815057812
oxt gene expression;increase;pvn;2;20026620150578031458365115057822399865140938892434861245099932037403233346216832075259437545100868347010066257153750271696529617355318180883591854997418601686191999541915043719207829105837281053142719258662107959091121960811427695118615301209791112535153125889011296003815057812
hypogonadism;inhibit;lh secretion;2;20080927
hypogonadism;inhibit;testosterone secretion;2;20080927
contrast;decrease;promoter activity e2 stimulation;0;16210360
182;suppress;780 antiestrogen;2;16210360
182;suppress;780 antiestrogen;2;16210360
estrogen;decrease;cell size density;0;19923782182181401741281718957836107200791095293311340263115810101158814511750181172412801698871711996929120067851207241014666141410310713496668346186638150658368826661121310281157385712802027678216769186281341057937331910113795393069706996973508610067842104652561633974419075656
treatment;increase;acth;2;21687973
treatment;increase;lh;2;21687973
contrast calcium level;increase;stimulation frequency;0;10995820
npy;increase;acth;2;16675522
npy;increase;corticosterone;0;16675522
npy;increase;secretion;0;16675522
npy;increase;crh;0;16675522
npy;increase;food intake;0;16675522
npy;increase;drinking;0;16675522
observation;decrease;alpha-msh injection;2;14614094
bloodstream secretion;decrease;alpha-msh injection;2;14614094
addition;inhibit;rat pituitary cell culture lh fsh expression;2;2451495311579200116751181168263111846609120061031191412412554749128472631976511192202618119298096199802753086129838557195980693110208743103931151441616116456148174971771853525618632661214649642147855110706142
3 mch 10 pituitary cell treatment;decrease;immunoreactivity area;0;19752150
release reduction;block;mch receptor treatment;2;19752150
release reduction;block;mchr treatment;2;19752150
grp;activate;scn neuron cluster;2;15758152120313451452308212042309124059671247086112492442125426551253621312684495128554161464858912930817147159391502615615071099150785481512007224133882112267839418213198002145056829896379820447705441770836576432058680427881753788419178990910924360994922071574916818318881076202810884333111819711120782011567064117522031175436612697032127523791293208612086606
dopamine;regulate;function;0;12486173
dopamine action;mediate;five receptor subtype;0;12486173
datum;increase;secretion;0;18032888
plasma vasopressin level;increase;period;0;17258819
result;increase;vasopressin half-life;2;17258819
estrogen;suppress;release pulse amplitude pulse frequency;0;15842235
progesterone concentration;decrease;pgfm pulse;2;19735938
ovx contrast;increase;release;0;15280536839505321655697724578883662288401279268384945050798257329831287100278781052013810688896107626681115862511239913112794971139488712052030120520441220716112383968125085691257897414981261481431247897792108882211917354336631235428270487517551
estrogen-primed contrast;increase;release;0;15280536839505321655697724578883662288401279268384945050798257329831287100278781052013810688896107626681115862511239913112794971139488712052030120520441220716112383968125085691257897414981261481431247897792108882211917354336631235428270487517551
ovx-e contrast;increase;release;0;15280536839505321655697724578883662288401279268384945050798257329831287100278781052013810688896107626681115862511239913112794971139488712052030120520441220716112383968125085691257897414981261481431247897792108882211917354336631235428270487517551
rat contrast;increase;release;0;15280536839505321655697724578883662288401279268384945050798257329831287100278781052013810688896107626681115862511239913112794971139488712052030120520441220716112383968125085691257897414981261481431247897792108882211917354336631235428270487517551
estrogenic compound;block;estrogen function;0;1701020768729471145985028263422717621267619622496311877066115814961180016911854024118698251193622211993862120145751206290112075121124029791254059612655037127591001465425115243276506131131873671935111511778849934783088868013351772379776326177592907758828185938818593856891976890485849348186953900497212541019150110395934155859441583489810552479105640251058074310917909114296463840114
oestrogen receptor;regulate;development;0;16280024
oestrogen receptor;regulate;function;0;16280024
npy + nmma;increase;lh;2;12011801
50 microg;increase;lh;2;12011801
incubation;decrease;lh release;2;12011801
npy;decrease;vitro release;0;12011801
observation;decrease;alpha-msh injection;2;14614094
bloodstream secretion;decrease;alpha-msh injection;2;14614094
dopamine effect;mediate;receptor;0;11504182
dopamine effect;mediate;receptor subtype;0;11504182
vasopressin;activate;urea transport;0;16641165
vasopressin;block;opc-31260;0;16641165
flutamide androgen receptor antagonism;increase;lh fsh level;2;11354908
(3)- dexamethasone therapy;increase;survival rate;0;19141191
